

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
1. Infectious and Parasitic Diseases							
Rabies Vaccine							
1	69	Systemic reaction to rabies vaccine	0.56		Clinicians	Time Trade Off	
1	69	Local reaction to rabies vaccine	0.99	0.7803-0.99	Clinicians	Time Trade Off	
Tuberculosis (TB)							
1	25	Near-death time spent in hospital with TB	0.10		Authors	Author/Clinical Judgement	
1	198	Near-death time spent in hospital TB	0.10		Authors	Author/Clinical Judgement	
1	25	Time spent in hospital with non-fatal TB	0.50		Authors	Author/Clinical Judgement	
1	198	Time spent in hospital w/non-fatal illness (TB)	0.50		Authors	Author/Clinical Judgement	
1	198	Sick time at home with TB	0.90		Authors	Author/Clinical Judgement	
1	25	Outpatient treatment/ sick time at home (TB)	0.90		Authors	Author/Clinical Judgement	
1	198	Outpatient treatment of TB	0.90		Authors	Author/Clinical Judgement	
Varicella							
1	117	Hospitalization for adults with varicella	0.50		Authors	Author/Clinical Judgement	
1	117	Varicella illness in adults	0.80		Authors	Author/Clinical Judgement	
1	117	Herpes zoster	0.80		Authors	Author/Clinical Judgement	
Antibiotics/General							
1	19	A course of prophylactic antibiotics for joint infection	0.999986		Authors	Author/Clinical Judgement	
1	36	Minor toxicity from Pneumocystis Carinii (PCP) prophylaxis	1.00	0.96-1	Authors	Author/Clinical Judgement	
1	44	Minor toxicity from antibiotics to treat Pneumocystis Carinii (PCP)	0.997	0.997-1	Authors	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
1	36	Major toxicity from Pneumocystis Carinii (PCP) prophylaxis	1.00	0.861-1	Authors	Author/Clinical Judgement	
1	44	Major toxicity from antibiotics to treat Pneumocystis Carinii (PCP)	0.989	0.945-1	Authors	Author/Clinical Judgement	
1	36	Trimethoprim-sulfamethoxazole for Pneumocystis Carinii (PCP) prophylaxis	1.00	0.5-1	Authors	Author/Clinical Judgement	
1	44	Outpatient Trimethoprim-sulfamethoxazole for Pneumocystis Carinii (PCP)	0.99993	0.997-1	Authors	Author/Clinical Judgement	
1	44	Inpatient Trimethoprim-sulfamethoxazole for Pneumocystis Carinii (PCP)	0.997	0.997-1	Authors	Author/Clinical Judgement	
1	36	Aerosolized pentamidine for Pneumocystis Carinii (PCP) prophylaxis	1.00	0.5-1	Authors	Author/Clinical Judgement	
1	44	Outpatient Pentamidine for Pneumocystis Carinii (PCP)	0.9997	0.997-1	Authors	Author/Clinical Judgement	
1	44	Inpatient Pentamidine for Pneumocystis Carinii (PCP)	0.997	0.997-1	Authors	Author/Clinical Judgement	
1	44	Outpatient Erythromycin	0.99993	0.997-1	Authors	Author/Clinical Judgement	
1	95	Oral antibiotic therapy to treat diabetic foot ulcers	0.99		Clinicians	Author/Clinical Judgement	
1	172	Major toxicity of doxycycline for Lyme disease (causing discontinuation of meds)	0.90		Clinicians		
1	172	Minor toxicity of antibiotic therapy (GI intolerance) for Lyme disease	0.95		Clinicians		
1	172	Intravenous antibiotic therapy for Lyme disease (ceftriaxone)	0.97	0-1	Clinicians		
1	172	Oral antibiotic therapy for Lyme disease (doxycycline)	0.99	0-1	Clinicians		
1	208	Bacteremia	0.21		Community		Years of Health Life Index (YHL)
HIV/AIDS							
1	49	HIV infection (pre-AIDS)	0.50	0.3-0.8	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
1	67	HIV infection (pre-AIDS)	0.50	0.3-0.8	Clinicians, Authors	Author/Clinical Judgement	
1	97	HIV infection	0.75		Authors	Author/Clinical Judgement	
1	164	Asymptomatic HIV infection	1.00		Clinicians	Author/Clinical Judgement	

Catalog of Preference Scores							
<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
1	214	HIV infection survival with treatment-induced toxicity	0.50	0.5-0.8	Authors	Author/Clinical Judgement	
1	214	HIV infection survival with disease progression	0.50	0.4-0.6	Authors	Author/Clinical Judgement	
1	214	HIV infection survival without symptoms or toxicity	1.00		Authors	Author/Clinical Judgement	
1	164	Symptomatic infection or reduced t cell counts	0.70		Clinicians	Author/Clinical Judgement	
1	49	AIDS	0.25	0-0.5	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
1	67	AIDS	0.25	0-0.5	Clinicians, Authors	Author/Clinical Judgement	
1	97	AIDS	0.50		Authors	Author/Clinical Judgement	
1	164	AIDS	0.50		Clinicians	Author/Clinical Judgement	
2		2. Neoplasms					
		Liver Cancers					
2	115	Primary liver cancer	0.20		Authors	Author/Clinical Judgement	
2	126	Hepatocellular carcinoma	0.49	0.14-0.84	Clinicians	Standard Gamble, Time Trade Off	
2	209	hepatocellular carcinoma	0.25		Clinicians	Author/Clinical Judgement	
2	216	Hepatocellular cancer	0.10	0.02-0.50	Clinicians	Time Trade Off, Rating Scale	
		Gastrointestinal Cancer					
2	171	Delaying diagnosis of gastric cancer by six weeks	0.97	0-0.99	Community		Quality of Well-Being Scale (QWB)
2	177	Colorectal cancer	0.95		Authors	Author/Clinical Judgement	
2	211	Dukes' B or C colorectal cancer	0.83	0.46-0.81	Patients		

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
2	61	Post-surgery for colonic carcinmoa	1.00		Community, Patientsh	Time Trade Off	
2	186	Surgery for colon cancer, no relapse	0.83		Community, Patients		EuroQoL
2	68	Systemic relapse of colon cancer	0.50		Authors	Author/Clinical Judgement	
2	186	Surgery for colon cancer, relapse	0.83		Community, Patients		EuroQoL
2	21	Incurable colon cancer	0.75	0.5-1.0	Authors	Author/Clinical Judgement	
2	61	Chemotherapy for colonic carcinoma, with bad side effects	0.80		Community, Patients	Time Trade Off	
2	61	Chemotherapy for colonic carcinoma with medium side effects	0.88		Community, Patients	Time Trade Off	
2	61	Chemotherapy for colonic carcinoma with good side effects	0.93		Community, Patients	Time Trade Off	
2	68	Adjuvant treatment for colon cancer	0.80		Authors	Author/Clinical Judgement	
2	186	Chemotherapy for colon cancer, no relapse	0.83		Community, Patients		EuroQoL
2	186	Chemotherapy for colon cancer, relapse (5 year survival raised by 5-15%, all the same utility)	0.83		Community, Patients		EuroQoL
Genitourinary Cancers							
2	28	Endometrial CA	0.80		Authors		
2	177	Cervical cancer	0.99		Authors	Author/Clinical Judgement	
2	197	Short-term morbidity relating to cervical cancer screening	0.90				
2	197	Long-term morbidity relating to cervical cancer screening	0.75				
2	218	Ovarian Cancer no response to Ifosfamide	0.37		Patients	Time Trade Off	
2	218	Ovarian Cancer response to Ifosfamide	0.50		Patients	Time Trade Off	
2	218	Ovarian Cancer no response to Paclitaxel	0.37		Patients	Time Trade Off	
2	218	Ovarian Cancer response to Paclitaxel	0.43		Patients	Time Trade Off	
2	218	Ovarian Cancer no response to Hexamethylmelamine	0.43		Patients	Time Trade Off	
2	218	Ovarian Cancer response to Hexamethylmelamine	0.55		Patients	Time Trade Off	
2	218	Ovarian Cancer no response to Tamoxifen	0.52		Patients	Time Trade Off	
2	218	Ovarian Cancer response to Tamoxifen	0.65		Patients	Time Trade Off	
2	218	Ovarian Cancer response to Cyclophosphamide and Cisplatin	0.65		Patients	Time Trade Off	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
2	218	Ovarian Cancer response to Paclitaxel and Cisplatin	0.71		Patients	Time Trade Off	
2	40	Survive after penile cancer (per year)	0.50	0-1	Authors	Author/Clinical Judgement	
2	130	Stable prostate carcinoma (asymptomatic)	0.92		Clinicians	Time Trade Off	
2	130	Early progressive prostate carcinoma (moderate pain/fatigue)	0.83	0.41-1	Clinicians	Time Trade Off	
2	130	Late progressive prostate carcinoma (severe pain/fatigue)	0.42		Clinicians	Time Trade Off	
2	78	Metastatic prostate cancer disease	0.58		Clinicians	Time Trade Off	
2	78	Disutility from radical prostatectomy	0.9041		Clinicians	Time Trade Off	
2	78	Disutility from external-beam radiotherapy for prostate cancer	0.9425		Clinicians	Time Trade Off	
2	78	Disutility from transurethral resection of prostate	0.9425		Clinicians	Time Trade Off	
2	78	Disutility from orchiectomy	0.9616		Clinicians	Time Trade Off	
2	78	Disutility from transrectal ultrasound & biopsy	0.9973		Clinicians	Time Trade Off	
2	130	Stable prostate carcinoma with GI side effects from Flutamide	0.84		Clinicians	Time Trade Off	
Breast Cancer							
2	34	Breast cancer screening examination	0.99		Clinicians	Rating Scale	
2	34	Breast cancer assessment/biopsy	0.89		Clinicians	Rating Scale	
2	34	Primary surgery for breast cancer	0.87		Clinicians	Rating Scale	
2	34	After breast-conserving therapy	0.91		Clinicians	Rating Scale	
2	34	After breast-conserving therapy instead of mastectomy	0.93		Clinicians	Rating Scale	
2	213	After mastectomy	0.84	0.80-0.85	Community, Patients		EuroQoL
2	213	After breast-conserving surgery	0.87		Community, Patients		EuroQoL
2	46	Complete remission breast CA	0.85	0.8-1	Clinicians	Rating Scale	
2	150	Breast cancer prior to chemotherapy	0.86		Clinicians	Standard Gamble	
2	177	Breast cancer	0.97		Clinicians	Rating Scale	
2	219	Poor health with breast cancer age 45-54	0.26		Community, Patients	Time Trade Off	
2	219	Poor health with breast cancer age 55-64	0.30		Community, Patients	Time Trade Off	
2	219	Poor health with breast cancer age 65-69	0.18		Community, Patients	Time Trade Off	
2	219	Good health with breast cancer age 45-54	0.58		Community, Patients	Time Trade Off	
2	219	Good health with breast cancer age 55-64	0.59		Community, Patients	Time Trade Off	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
2	219	Good health with breast cancer age 65-69	0.32		Community, Patients	Time Trade Off	
2	45	Complete response to chemotherapy for breast cancer	0.85		Clinicians		
2	150	Confirmed responder to breast cancer chemotherapy	0.81		Clinicians	Standard Gamble	
2	150	Confirmed responder to breast cancer chemotherapy with treatment interrupted due to neuropathy	0.57		Clinicians	Standard Gamble	
2	150	Confirmed responder to breast cancer chemotherapy with severe neuropathy	0.75		Clinicians	Standard Gamble	
2	150	Confirmed responder to breast cancer chemotherapy with treatment interrupted due to edema	0.64		Clinicians	Standard Gamble	
2	150	Confirmed responder to breast cancer chemotherapy with severe edema	0.74		Clinicians	Standard Gamble	
2	46	Stable disease breast cancer	0.50	0.3-1	Clinicians	Rating Scale	
2	150	Stable breast cancer with severe edema	0.58		Clinicians	Standard Gamble	
2	150	Stable breast cancer with treatment interrupted due to edema	0.58		Clinicians	Standard Gamble	
2	150	Stable breast cancer with severe edema	0.73		Clinicians	Standard Gamble	
2	150	Stable breast cancer with severe neuropathy	0.65		Clinicians	Standard Gamble	
2	150	Stable breast cancer with treatment interrupted due to neuropathy	0.50		Clinicians	Standard Gamble	
2	38	First recurrence - breast cancer	0.70	0.6-0.8	Clinicians		
2	45	First recurrence - breast cancer	0.70		Clinicians		
2	50	First recurrence - breast cancer	0.70	0.5-1			
2	53	First recurrence of breast cancer	0.70		Authors	Rating Scale	
2	63	First recurrence - breast cancer	0.70	0.5-1	Clinicians		
2	38	After first recurrence - breast cancer	0.85	0.7-0.9	Clinicians		
2	63	After first recurrence - breast cancer	0.85	0.6-0.8	Clinicians		
2	141	Breast cancer before second line therapy begins	0.56		Clinicians	Standard Gamble	
2	141	Stable breast cancer disease following second line taxoid treatment	0.62		Clinicians	Standard Gamble	
2	38	Second recurrence - breast cancer	0.50	0.4-0.6	Clinicians		
2	63	Second recurrence - breast cancer	0.50	0.7-0.9	Clinicians		
2	38	After second recurrence -breast cancer	0.70	0.6-0.8	Clinicians		
2	63	After second recurrence - breast cancer	0.70	0.4-0.6	Clinicians		
2	38	Third recurrence - breast cancer	0.30	0.2-0.4	Clinicians		
2	45	Third recurrence - breast cancer	0.30		Clinicians		
2	63	Third recurrence - breast cancer	0.30	0.2-0.4	Clinicians		
2	46	Partial remission - breast cancer	0.60	0.5-1	Clinicians	Rating Scale	
2	141	Partial response with severe peripheral neuropathy to taxoid treatment of breast cancer	0.62		Clinicians	Standard Gamble	
2	141	Partial response with severe peripheral edema to taxoid treatment for breast cancer	0.78		Clinicians	Standard Gamble	
2	141	Partial response to second line taxoid treatment for breast cancer	0.84		Clinicians	Standard Gamble	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
2	150	Early progression of breast cancer	0.52		Clinicians	Standard Gamble	
2	46	Progressive disease breast cancer	0.40	0.2-1	Clinicians	Rating Scale	
2	141	Progressive disease breast cancer	0.33		Clinicians	Standard Gamble	
2	150	Progressive disease breast cancer	0.58		Clinicians	Standard Gamble	
2	150	Progressive disease breast cancer with severe edema	0.53		Clinicians	Standard Gamble	
2	150	Progressive disease breast cancer with treatment interrupted due to edema	0.50		Clinicians	Standard Gamble	
2	150	Progressive disease breast cancer with severe neuropathy	0.25		Clinicians	Standard Gamble	
2	150	Progressive disease breast cancer with treatment interrupted due to neuropathy	0.45		Clinicians	Standard Gamble	
2	34	Advanced breast cancer disease terminal phase	0.29		Clinicians	Rating Scale	
2	141	Advanced breast cancer disease terminal phase	0.13		Clinicians	Standard Gamble	
2	141	Breast cancer with sepsis	0.16		Clinicians	Standard Gamble	
		Breast Cancer Treatments					
2	34	Primary radiotherapy for breast cancer	0.80		Clinicians	Rating Scale	
2	63	Treatment with tamoxifen	0.99	0.7-1	Clinicians		
2	34	Adjuvant systemic therapy for breast cancer	0.82		Clinicians	Rating Scale	
2	46	Induction high dose chemotherapy (doxorubicin, methotrexate, fluorouracil) for breast cancer	0.50	0.3-1	Clinicians	Rating Scale	
2	46	Standard chemotherapy (cyclophosphamide, doxorubicin, fluorouracil) for breast cancer	0.70	0.5-1	Clinicians	Rating Scale	
2	38	Major toxicity with chemotherapy - breast cancer	0.80	0.5-0.95	Clinicians		
2	45	Chemotherapy major toxicity for breast cancer (requiring hospitalization)	0.80		Clinicians		
2	50	Major toxicity with chemotherapy (cyclophosphamide, doxorubicin, fluorouracil) for breast cancer	0.80	0.5-1			
2	63	Major toxicity with chemotherapy for breast cancer	0.70	0.5-0.95	Clinicians		
2	38	Minor toxicity with chemotherapy for breast cancer	0.90	0.7-1	Clinicians		
2	50	Minor toxicity with chemotherapy (cyclophosphamide, doxorubicin, fluorouracil) for breast cancer	0.90	0.5-0.95			
2	45	Minor toxicity breast cancer chemotherapy	0.90		Clinicians		
2	63	Minor toxicity breast cancer chemotherapy	0.90	0.9-1	Clinicians		
2	150	Minor toxicity breast cancer chemotherapy	0.76		Clinicians	Standard Gamble	
2	150	Febrile neutropenia from breast cancer chemotherapy without hospitalization	0.66		Clinicians	Standard Gamble	
2	150	Febrile neutropenia from breast cancer chemotherapy with hospitalization	0.47		Clinicians	Standard Gamble	
2	150	Severe skin reaction breast cancer chemotherapy	0.72		Clinicians	Standard Gamble	
2	150	Severe arthralgia/myalgia from breast cancer chemotherapy	0.72		Clinicians	Standard Gamble	
2	150	GI toxicity with hospitalization from breast cancer chemotherapy	0.48		Clinicians	Standard Gamble	
2	46	Complicated bone marrow transplant for breast cancer	0.10	0.05-1	Clinicians	Rating Scale	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	(listed below)						
2	46	Uncomplicated bone marrow transplant for breast cancer	0.30	0.1-1	Clinicians	Rating Scale	
2	34	Advanced breast cancer treatment	0.63		Clinicians	Rating Scale	
		Lung cancer					
2	190	No test of lung lesion	0.70		Authors	Author/Clinical Judgement	
2	190	Sputum test of lung lesion	0.90		Authors	Author/Clinical Judgement	
2	190	Fine needle aspiration of lung lesion	0.90		Authors	Author/Clinical Judgement	
2	190	Thoracoscopy of lung lesion (with more risk-aversion)	0.50		Authors	Author/Clinical Judgement	
2	190	Thoracoscopy of lung lesion (with less risk-aversion)	0.70		Authors	Author/Clinical Judgement	
2	190	Lung lesion test complication	0.90		Authors	Author/Clinical Judgement	
2	190	Thoracoscopy complication	0.70		Authors	Author/Clinical Judgement	
2	190	Concern over false-positive diagnosis of lung lesion from test result (less risk-aversion)	0.80		Authors	Author/Clinical Judgement	
2	190	Concern over false-negative diagnosis of lung lesion from test result	0.60		Authors	Author/Clinical Judgement	
2	190	Concern over false-positive diagnosis of lung lesion from test result (more risk-aversion)	0.40		Authors	Author/Clinical Judgement	
2	190	Indeterminate diagnosis of lung lesion from test result, with cancer	0.60		Authors	Author/Clinical Judgement	
2	190	Indeterminate diagnosis of lung lesion from test result, with no cancer	0.80		Authors	Author/Clinical Judgement	
2	14	Complete remission of small cell lung cancer	0.87		Clinicians, Patients	Rating Scale	
2	14	Partial remission of small cell lung cancer	0.73		Clinicians, Patients	Rating Scale	
2	14	Small cell lung cancer disease progression	0.15		Clinicians, Patients	Rating Scale	
2	190	Local-stage lung cancer	0.60		Authors	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
2	190	Regional-stage lung cancer	0.50		Authors	Author/Clinical Judgement	
2	190	Distant-stage lung cancer	0.40		Authors	Author/Clinical Judgement	
2	93	Morbidity of thoracotomy and craniotomy for lung cancer + brain mets	0.917				
2	190	Expectant management of lung lesion (with less risk-aversion)	0.90		Authors	Author/Clinical Judgement	
2	190	Expectant management of lung lesion (with more risk-aversion)	0.75		Authors	Author/Clinical Judgement	
2	190	Lung cancer stage-related complication	0.85		Authors	Author/Clinical Judgement	
2	14	CAV chemotherapy for small cell lung cancer	0.52		Clinicians, Patients	Rating Scale	
2	14	VP-16/cisplatin chemotherapy for small cell lung cancer	0.54		Clinicians, Patients	Rating Scale	
2	14	Radiation therapy for small cell lung cancer	0.65		Clinicians, Patients	Rating Scale	
Leukemias and Myeloma							
2	32	Survival with leukemia (without bone marrow transplantation)	0.956		Community, Clinicians, Patients, Authors		Rosser index
2	146	Acceleration of chronic myelogenous leukemia	0.50		Clinicians	Author/Clinical Judgement	
2	183	Blast crisis in chronic myelogenous leukemia	0.50		Clinicians	Rating Scale	
2	146	Chronic myelogenous leukemia blast crisis, months 1-4	0.50		Clinicians	Author/Clinical Judgement	
2	146	Chronic myelogenous leukemia blast crisis, after month 4	0.50		Clinicians	Author/Clinical Judgement	
2	183	Interferon alfa treatment for chronic myelogenous leukemia	0.875	0.7-0.95	Clinicians	Rating Scale	
2	146	Interferon-alpha therapy for chronic myelogenous leukemia	0.90	0.62-1	Clinicians	Author/Clinical Judgement	
2	183	Busulfan treatment for chronic myelogenous leukemia	0.94	0.85-0.95	Clinicians	Rating Scale	
2	146	Hydroxyurea therapy for chronic myelogenous leukemia	1.00		Clinicians	Author/Clinical Judgement	
2	183	Hydroxyurea treatment for chronic myelogenous leukemia	0.98	0.95-1	Clinicians	Rating Scale	
2	146	Bone marrow transplantation for chronic myelogenous leukemia, month 1	0.00		Clinicians	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	(listed below)						
2	146	Bone marrow transplantation for chronic myelogenous leukemia, after month 1	0.95		Clinicians	Author/Clinical Judgement	
2	42	Chronic lymphocytic leukemia with major infection	0.46	0.2-0.9	Clinicians	Standard Gamble	
2	42	Chronic lymphocytic leukemia with moderate infection	0.81	0.5-0.99	Clinicians	Standard Gamble	
2	42	Chronic lymphocytic leukemia with trivial infection	0.86	0.5-0.999	Clinicians	Standard Gamble	
2	42	Chronic lymphocytic leukemia without infection	0.87	0.5-0.999	Clinicians	Standard Gamble	
2	32	Last month of life with leukemia	0.00		Community, Clinicians, Patients, Authors		Rosser index
2	185	Melphalan plus prednisone for myeloma	0.65		Community		15-D (15-Dimensional measure of health-related quality of life)
2	185	Melphalan plus prednisone plus interferon for myeloma	0.65		Community		15-D (15-Dimensional measure of health-related quality of life)
Lymphoma							
2	123	Non-Hodgkins lymphoma treated with bone marrow transplant and no remission	0.573		Community, Patients		EuroQoL
2	123	Non-Hodgkins lymphoma treated with bone marrow transplant and remission at 6 mo.	0.63		Community, Patients		EuroQoL
2	123	Non-Hodgkins lymphoma treated with bone marrow transplant and remission at 1 yr.	0.84		Community, Patients		EuroQoL
2	123	Non-Hodgkins lymphoma treated with bone marrow transplant and remission at 2 years	0.91		Community, Patients		EuroQoL
2	123	Non-Hodgkins lymphoma treated with CHOP with no remission	0.573		Community, Patients		EuroQoL
2	123	Non-Hodgkins lymphoma treated with CHOP, with remission at 6 months	0.78		Community, Patients		EuroQoL
2	123	Non-Hodgkins lymphoma treated with CHOP, with remission at 1 year	0.81		Community, Patients		EuroQoL
2	123	Non-Hodgkins lymphoma treated with CHOP, with remission at 2 years	0.92		Community, Patients		EuroQoL

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
2	154	Untreated Hodgkin's disease	0.14	0.14-0.5	Community, Clinicians, Patients		EuroQoL
2	154	Hodgkin's disease stage II survivors following treatment	0.73	0.6-0.9	Community, Clinicians, Patients		EuroQoL
2	154	Hodgkin's disease stage I survivors following treatment	0.77	0.6-0.9	Community, Clinicians, Patients		EuroQoL
2	154	Hodgkin's disease stage III survivors following treatment	0.85	0.6-0.9	Community, Clinicians, Patients		EuroQoL
2	154	Hodgkin's disease stage IV survivors following treatment	0.81	0.6-0.9	Community, Clinicians, Patients		EuroQoL
Melanoma							
2	176	Melanoma disease-free, no treatment	1.00	0.95-1	Authors	Author/Clinical Judgement	
2	205	Complete remission of melanoma surgical patient	0.90	0.85-0.96	Clinicians	Author/Clinical Judgement	
2	205	Melanoma - metastatic disease	0.50	0.15-0.6	Clinicians	Author/Clinical Judgement	
2	176	Recurrent melanoma disease	0.50	0-1	Authors	Author/Clinical Judgement	
2	176	Induction of interferon (IFN alpha 2b) for melanoma	0.70	0-1	Authors	Author/Clinical Judgement	
2	176	Maintenance interferon (IFN alpha 2b) for melanoma	0.80	0-1	Authors	Author/Clinical Judgement	
3		3. Endocrine, Nutritional, and Metabolic Diseases and Immunity Disorders					
Nutrition							
3	157	Intestinal failure without home parenteral nutrition (HPN)	0.18		Patients	Rating Scale	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
3	157	Intestinal failure patient with home parenteral nutrition (HPN)	0.52	0.28-0.61	Community, Patients		EuroQoL
Thyroid							
3	133	Euthyroid	1.00			Author/Clinical Judgement	
3	133	Mild Thyroid Failure-symptoms	0.90	0.8-1	Authors	Author/Clinical Judgement	
3	133	Overt hypothyroidism	0.74	0.5-0.9	Clinicians	Rating Scale	
3	133	Complicated myxedema	0.40	0.1-0.5	Authors	Author/Clinical Judgement	
3	10	Hypothyroidism without treatment, year 1	0.7085		Community		Quality of Well-Being Scale (QWB)
3	10	Hypothyroidism without treatment, year 2+	0.6053		Community		Quality of Well-Being Scale (QWB)
3	10	Hypothyroidism with treatment, year 1	0.8577		Community		Quality of Well-Being Scale (QWB)
3	10	Hypothyroidism with treatment, year 2+	0.8557		Community		Quality of Well-Being Scale (QWB)
3	10	Hyperthyroidism without treatment, year 1	0.7406		Community		Quality of Well-Being Scale (QWB)
3	10	Hyperthyroidism without treatment, year 2+	0.6451		Community		Quality of Well-Being Scale (QWB)
3	10	Hyperthyroidism with treatment, yr. 1	0.9755		Community		Quality of Well-Being Scale (QWB)
3	10	Hyperthyroidism with treatment, year 2+	0.951		Community		Quality of Well-Being Scale (QWB)
Diabetes							
3	109	Insulin dependent diabetes melitus	0.838		Clinicians	Time Trade Off	
3	90	Diabetes & congestive heart failure	0.87		Authors	Author/Clinical Judgement	
3	90	Diabetes	0.90		Authors	Author/Clinical Judgement	
Immune							
3	18	Minor reaction to contrast media	1.00		Authors	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
3	18	Major reaction to contrast media	0.70		Authors Clinicians	Author/Clinical Judgement	
3	156	Serum Sickness Like-reaction adverse event during treatment of Acute Otitis Media	0.53	0.412-0.648		Rating Scale	
3	69	Immune complex-like reaction to rabies vaccine	0.57		Clinicians	Time Trade Off	
3	42	Intravenous immune globulin infusion	0.87	0.2-0.99	Clinicians	Standard Gamble	
Sex Hormones							
3	3	Menopausal symptoms	0.99				
3	28	Estrogen-progestin treatment	+ 0	- 0.02 - + 0.02	Authors		
3	28	Estrogen treatment	+ 0.02	+ 0 - + 0.02	Authors		
4	4. Diseases of the Blood and Blood-Forming Organs						
Blood and Blood Forming Organs							
4	148	Immune Thrombocytopenic Purpura	0.8799	0.8742-0.8887	Authors	Author/Clinical Judgement	
4	148	Protein A Immunoabsorption column treatment for Immune Thrombocytopenic Purpura	0.9608	0.94-0.98	Authors	Author/Clinical Judgement	
4	148	Splenectomy for Immune Thrombocytopenic Purpura	0.9608	0.94-0.98	Authors	Author/Clinical Judgement	
4	148	Remission of Immune Thrombocytopenic Purpura	1.00		Authors	Author/Clinical Judgement	
5	5. Mental Disorders						
Caregivers							
5	35	Caregiver quality of life 6 months of standard care - demented patient	0.53		Relatives/Proxies	Time Trade Off	
5	35	Caregiver quality of life 6 months of Caregiver Support Program - demented patient	0.64		Relatives/Proxies	Time Trade Off	
5	117	Caregiver distress for children with varicella infection	0.80		Authors	Author/Clinical Judgement	
Depression							
5	119	Untreated depression	0.306		Patients	Standard Gamble	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
5	191	Depression symptoms, no treatment	0.31		Patients	Standard Gamble	
5	106	Depression	0.45	0.3-0.7	Community		Health Utilities Index (HUI) 1
5	119	Depression in remission, no treatment	0.895		Patients	Standard Gamble	
5	191	Remission from depression symptoms without treatment	0.89		Patients	Standard Gamble	
5	75	Depression in remission, off drug therapy	0.95		Clinicians	Standard Gamble	
5	106	Maintenance treatment, non-depressed	1.00	0.7-1	Community		Health Utilities Index (HUI) 1
5	75	Depression in remission, selective serotonin reuptake inhibitor maintenance therapy	0.93		Clinicians	Standard Gamble	
5	191	No depression symptoms, fluoxetine maintenance treatment	0.86		Patients	Standard Gamble	
5	75	Treatment of depressive episode with selective serotonin reuptake inhibitor	0.72		Clinicians	Standard Gamble	
5	119	Acute depressive episode, fluoxetine treatment	0.725		Patients	Standard Gamble	
5	191	Depression symptoms 1 month, fluoxetine treatment	0.72		Patients	Standard Gamble	
5	191	Depression symptoms 3 months, fluoxetine treatment	0.79		Patients	Standard Gamble	
5	119	3 months treatment, fluoxetine for depression	0.795		Patients	Standard Gamble	
5	119	Prophylaxis for depression, fluoxetine	0.859		Patients	Standard Gamble	
5	75	Treatment of depressive episode with tricyclic antidepressant	0.69		Clinicians	Standard Gamble	
5	119	Acute depressive episode, imipramine treatment	0.667		Patients	Standard Gamble	
5	191	Depression symptoms 1 month, imipramine treatment	0.67		Patients	Standard Gamble	
5	191	Depression symptoms 3 months, imipramine treatment	0.73		Patients	Standard Gamble	
5	119	3 months' treatment, imipramine for depression	0.734		Patients	Standard Gamble	
5	191	No depression symptoms, imipramine maintenance treatment	0.80		Patients	Standard Gamble	
5	119	Prophylaxis for depression, imipramine	0.797		Patients	Standard Gamble	
5	119	Acute depressive episode, nefazodone treatment	0.735		Patients	Standard Gamble	
5	191	Depression symptoms 1 month, nefazodone treatment	0.73		Patients	Standard Gamble	
5	119	3 months' treatment, nefazodone for depression	0.817		Patients	Standard Gamble	
5	191	Depression symptoms 3 months, nefazodone treatment	0.82		Patients	Standard Gamble	
5	191	No depression symptoms, nefazodone maintenance treatment	0.87		Patients	Standard Gamble	
5	119	Prophylaxis for depression, nefazodone	0.875		Patients	Standard Gamble	
Schizophrenia							
5	168	Mild schizophrenic symptoms	0.61	0.58	Clinicians	Standard Gamble, Rating Scale	
5	168	Moderate schizophrenic symptoms	0.36	0.35	Clinicians	Standard Gamble, Rating Scale	
5	168	Severe schizophrenic symptoms	0.29	0.25	Clinicians	Standard Gamble, Rating Scale	
5	163	Schizophrenia treated with clozapine	1.00			Rating Scale	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
5	163	Schizophrenia with clozapine treatment terminated	0.60			Rating Scale	
6		6. Diseases of the Nervous System and Sense Organs					
		Eyes					
6	56	Blindness	0.69				
6	128	Blindness due to diabetes	0.69				
6	143	Legal blindness for person "poorly-adjusted" after rehabilitation	0.36	0-0.9		Rating Scale	
6	55	Well-adjusted blind person	0.48				
6	143	Legal blindness for person "well-adjusted" after rehabilitation	0.48	0-0.9		Rating Scale	
6	217	Cytomegalovirus (CMV) retinitis	0.85				
		Ears and Hearing					
6	114	Trouble hearing	0.83		Community		Quality of Well-Being Scale (QWB)
6	82	Less severe sensorineural hearing loss due to Hemophilus influenza type B disease	0.91	0.79-1	Community, Clinicians, Patients		Health Utilities Index (HUI) 1
6	151	Partial auditory sequelae of Hemophilus influenza type B disease	0.977	0.9-1	Community, Clinicians, Patients		Rosser index
6	82	Hearing loss requiring hearing aid due to Hemophilus influenza type B disease	0.86	0.74-0.98	Community, Clinicians, Patients		Health Utilities Index (HUI) 1
6	162	Adult with profound deafness	0.588852		Community, Patients		Health Utilities Index (HUI) 3
6	102	Before cochlear implantation	0.639		Community		Quality of Well-Being Scale (QWB)
6	102	6 months post cochlear implantation	0.645		Community		Quality of Well-Being Scale (QWB)
6	102	1 year post cochlear implantation	0.72		Community		Quality of Well-Being Scale (QWB)
6	102	2 years post cochlear implantation	0.698		Community		Quality of Well-Being Scale (QWB)
6	102	2.5 years post cochlear implantation	0.686		Community		Quality of Well-Being Scale (QWB)

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
6	102	3 years post cochlear implantation	0.711		Community		Quality of Well-Being Scale (QWB)
6	162	Deaf adult with use of cochlear implant	0.79279	0.7-0.9	Community, Patients		Health Utilities Index (HUI) 3
6	224	Achievement of open-set speech understanding by deaf person	0.27		Community, Authors		Health Utilities Index (HUI) 2
6	114	Increased hearing with cochlear implant	0.89225		Community, Authors		Quality of Well-Being Scale (QWB)
6	156	Acute otitis media (AOM)	0.79	0.713-0.867	Clinicians	Rating Scale	
6	222	No cure of recurrent otitis media	0.50		Clinicians	Author/Clinical Judgement	
6	156	Persistence of AOM (treatment failure)	0.72	0.646-0.794	Clinicians	Rating Scale	
6	156	Resolution of Acute Otitis Media (treatment success)	0.96	0.942-0.978	Clinicians	Rating Scale	
6	222	Cure after antibiotics without recurrence of otitis media	1.00		Clinicians	Author/Clinical Judgement	
6	222	Cure after tube placement without recurrence of otitis media	0.99		Clinicians	Author/Clinical Judgement	
6	222	Cure after tube placement with recurrence of otitis media	0.90		Clinicians	Author/Clinical Judgement	
General Neurologic							
6	131	Paraplegia	0.72		Patients	Rating Scale	
6	221	Manual wheelchair	0.7004	0.6304-0.7704	Community		Index of Health-related Quality of Life (IHQL)
6	221	Electric wheelchair	0.8191	0.7372-0.901	Community		Index of Health-related Quality of Life (IHQL)
6	74	Mild neurological disability due to Hemophilus influenza type B disease	0.80	0.7-0.9	Authors	Author/Clinical Judgement	
6	82	Less severe neurological disability due to Hemophilus influenza type B disease	0.80	0.68-0.92	Community, Clinicians, Patients		Health Utilities Index (HUI) 1
6	151	Moderate sequelae of Hemophilus influenza type B disease	0.84	0.75-0.9	Community, Clinicians, Patients		Rosser index

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
6	82	Severe neurological disability due to Hemophilus influenza type B disease	0.88	0.73-0.997	Community, Clinicians, Patients		Health Utilities Index (HUI) 1
6	74	Severe neurological disability due to Hemophilus influenza type B disease	0.60	0.5-0.7	Authors	Author/Clinical Judgement	
6	151	Severe sequelae of Hemophilus influenza type B disease	0.371	0.3-0.5	Community, Clinicians, Patients		Rosser index
6	172	Neurologic symptoms of Lyme disease	0.95	0-1	Clinicians		
6	172	Transient neurologic symptoms of Lyme disease (1 month)	0.95		Clinicians		
6	57	Children with neurologic disability-mild	0.80	0.7-0.9	Authors	Author/Clinical Judgement	
6	170	Mild disability (developmental) - children	0.80	0.7-0.9	Authors	Author/Clinical Judgement	
6	57	Children with neurologic disability-moderate	0.60	0.4-0.8	Authors	Author/Clinical Judgement	
6	170	Moderate disability (developmental) - children	0.60	0.4-0.8	Authors	Author/Clinical Judgement	
6	57	Children with neurologic disability-severe	0.40	0.1-0.7	Authors	Author/Clinical Judgement	
6	170	Severe disability (developmental) - children	0.40	0.-0.7	Authors	Author/Clinical Judgement	
6	69	Major neurological reaction to rabies vaccine	0.31		Clinicians	Time Trade Off	
6	184	Severe multiple sclerosis (chronic progressive, nonambulatory)	0.36		Community		Health Utilities Index (HUI) 1
6	23	Persistent vegetative state	0.00		Authors	Author/Clinical Judgement	
6	100	Reading Disability	0.77	0.5-1	Clinicians	Rating Scale	
Dementia							
6	125	Global Deterioration Scale (for dementia) stage 4	0.6065		Community		Quality of Well-Being Scale (QWB)
6	125	Global Deterioration Scale (for dementia) stage 5, in house	0.5787		Community		Quality of Well-Being Scale (QWB)
6	125	Global Deterioration Scale (for dementia) stage 5, institutionalized in hospital	0.5356		Community		Quality of Well-Being Scale (QWB)
6	125	Global Deterioration Scale (for dementia) stage 6, institutionalized in hospital	0.4301		Community		Quality of Well-Being Scale (QWB)

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
6	125	Global Deterioration Scale (for dementia) stage 6, in house	0.4732		Community		Quality of Well-Being Scale (QWB)
6	125	Global Deterioration Scale (for dementia) stage 7, in house	0.4272		Community		Quality of Well-Being Scale (QWB)
6	125	Global Deterioration Scale (for dementia) stage 7, in special care unit	0.3517		Community		Quality of Well-Being Scale (QWB)
6	226	Net improvement from day care program for dementia patients	+ 0.53				
Seizures							
6	180	Complex partial or generalized seizures	0.67		Patients		
6	181	Epilepsy free of complex partial seizures, with auras only	0.80	0.74-0.86	Patients	Rating Scale	
6	181	Epilepsy free of complex partial seizures (CPS) or auras	0.89	0.8-0.98	Patients	Rating Scale	
6	181	Invasive monitoring & ATL (anterotemporal lobectomy)	0.962		Patients	Rating Scale	
6	181	Persisting complex partial seizures after medical management	0.62	0.62-0.72	Patients	Rating Scale	
6	181	Persisting complex partial seizures after anterotemporal lobectomy	0.72	0.68-0.74	Patients	Rating Scale	
6	180	Simple seizures and/or auras after epilepsy surgery	0.76		Patients		
6	180	Seizure free following epilepsy surgery	0.82	0.67-1	Patients		
7		7. Diseases of the Circulatory System					
		Cardiac/Cerebral Investigations & Procedures					
7	6	Undergoing angiography	1.00		Authors	Author/Clinical Judgement	
7	147	Undergoing angiography	0.9973		Patients	Time Trade Off	
7	30	Undergoing catheterization	0.997				
7	30	Undergoing angioplasty (PTCA)	0.992				
7	147	Undergoing angioplasty (PTCA)	0.9945		Patients	Time Trade Off	
7	70	PTCA or stenting	0.981		Authors	Author/Clinical Judgement	
7	70	Vascular complication (pseudoaneurysm, AV fistula) from angioplasty (PTCA)	0.981		Authors	Author/Clinical Judgement	
7	70	Restenosis after angioplasty (PTCA)	0.80		Authors	Author/Clinical Judgement	
7	116	Diagnosed coronary artery disease patients surviving 10 years after angioplasty (PTCA)	0.90				
7	116	Diagnosed coronary artery disease patients not surviving 10 years after angioplasty (PTCA)	0.60				

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
7	70	Coronary artery bypass surgery (CABG)	0.92		Authors	Author/Clinical Judgement	
7	30	Coronary artery bypass surgery (CABG)	0.917				
7	147	Coronary artery bypass surgery (CABG)	0.9726		Patients	Time Trade Off	
7	30	Coronary artery bypass surgery (CABG) post angioplasty (PTCA)	0.75				
7	116	Diagnosed coronary artery disease patients not surviving 10 yrs. after coronary artery bypass surgery	0.50				
7	116	Diagnosed coronary artery disease patients surviving 10 yrs. after coronary artery bypass surgery	0.90				
7	64	Severe permanent morbidity from valve surgery/outlet strut function	0.50		Authors	Author/Clinical Judgement	
7	169	Carotid endarterectomy	0.9615		Authors	Author/Clinical Judgement	
7	169	Carotid Arteriogram	0.999		Authors	Author/Clinical Judgement	
7	111	Recovery period (3 months) after aneurysm repair with normal function	0.75		Authors	Author/Clinical Judgement	
		Cardiac Arrhythmia					
7	54	Heart block	0.99		Authors	Author/Clinical Judgement	
7	54	Paroxysmal supraventricular tachycardia/atrial fibrillation with hemodynamic compromise	0.90		Clinicians		
7	54	Paroxysmal supraventricular tachycardia/atrial fibrillation	0.95		Clinicians		
7	188	Arrhythmic event while receiving amiodarone	0.99	0.92-1	Authors	Author/Clinical Judgement	
7	54	Cardiac arrest episode	0.85		Clinicians		
7	108	Living after hospitalization for cardiac arrest	0.99		Community, Clinicians, Patients		Rosser index
7	153	Post discharge from hospital after out-of-hospital cardiac arrest	0.84		Patients	Standard Gamble	
7	188	Current health after surviving sudden cardiac death	0.75	0.25-1	Community, Patients		Beaver Dam Health Outcomes Study
7	188	Neurologic impairment after sudden cardiac death	0.56	0-0.75	Authors	Author/Clinical Judgement	
7	188	Taking Amiodarone	0.75	0.25-0.75	Authors	Author/Clinical Judgement	
7	54	Antiarrhythmic drug side effect	0.95		Clinicians		

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	(listed below)						
7	188	Acute drug toxicity (amiodarone)	0.998	0.92-1	Authors		
7	54	Surgery for arrhythmia	0.95		Clinicians		
7	188	Implantable cardioverter defibrillator	0.75	0.25-0.75	Authors	Author/Clinical Judgement	
7	188	During implantable cardioverter defibrillator (ICD) implantation	0.98	0.92-1	Authors	Author/Clinical Judgement	
7	188	Lead complication (from implantable defibrillator)	0.99	0.997-1	Patients	Author/Clinical Judgement	
Myocardial Infarction							
7	192	Unrecognized myocardial infarction (MI)	0.95		Patients	Time Trade Off	
7	192	Recognized myocardial infarction (MI)	0.90		Patients	Time Trade Off	
7	133	Myocardial infarction (MI)	0.87	0.75-0.95	Patients	Time Trade Off	
7	70	Myocardial infarction (MI)	0.973		Authors	Author/Clinical Judgement	
7	66	Myocardial infarction (MI) after angiogram	0.70	0.5-0.9			
7	30	Myocardial infarction (MI)	0.981				
7	200	In-hospital post-myocardial infarction (MI)	0.33		Clinicians, Patients		Health Utilities Index (HUI) 1
7	47	In-hospital with suspected myocardial infarction (MI)	0.30				
7	203	Hospitalization for myocardial infarction (MI), revascularization, cardiac arrest	0.00		Patients		
7	105	Reinfarction following myocardial infarction (MI)	0.93		Patients	Time Trade Off	
7	147	Subsequent myocardial infarction (MI)	0.9808		Patients	Time Trade Off	
7	200	Post-myocardial infarction (MI) in NYHA functional class I	1.00		Clinicians, Patients		Health Utilities Index (HUI) 1
7	200	Post-myocardial infarction (MI) in NYHA functional class II	0.70		Clinicians, Patients		Health Utilities Index (HUI) 1
7	200	Post-myocardial infarction (MI) in NYHA functional class III/IV	0.50		Clinicians, Patients		Health Utilities Index (HUI) 1
7	147	Post-myocardial infarction (MI), with no angina, no congestive heart failure	0.93		Patients	Time Trade Off	
7	182	Post-myocardial infarction (MI)	0.88		Patients	Time Trade Off	
7	105	Neither stroke nor reinfarction following myocardial infarction (MI)	0.95		Patients	Time Trade Off	
7	134	Stroke-free post-myocardial infarction (MI)	0.90	0.7-1	Patients	Time Trade Off	
7	179	Stable and asymptomatic after surviving an myocardial infarction (MI)	0.90		Authors	Author/Clinical Judgement	
7	37	Survival after myocardial infarction (MI), 1st year	0.937		Community, Clinicians, Patients		Rosser index

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
7	1	1st year post myocardial infarction (MI)	0.80		Authors	Author/Clinical Judgement	
7	1	Subsequent years (after 1st) post myocardial infarction (MI)	0.95		Authors	Author/Clinical Judgement	
7	122	Captopril therapy after myocardial infarction (MI)	0.88	0-1	Patients	Time Trade Off	
7	122	Captopril Placebo after myocardial infarction (MI)	0.89	0.83-0.93	Patients	Time Trade Off	
Angina							
7	206	Coronary heart disease compared to same age	0.90		Community		
7	203	History of coronary artery disease but asymptomatic (no angina or congestive heart failure)	0.902		Patients	Time Trade Off	
7	15	Coronary heart disease	0.80	0.7-0.9	Authors	Author/Clinical Judgement	
7	133	Angina	0.75	0.5-0.9	Authors	Author/Clinical Judgement	
7	192	Coronary insufficiency	0.90		Patients	Time Trade Off	
7	192	Angina	0.90		Patients	Time Trade Off	
7	203	Angina (no congestive heart failure)	0.841		Patients	Time Trade Off	
7	203	Angina and congestive heart failure	0.736		Patients	Time Trade Off	
7	47	NYHA functional class I angina	1.00				
7	5	Mild angina in person who values activity highly	0.70	0.75	Community	Standard Gamble	
7	5	Mild angina in sedentary person	0.80	0.95	Community	Standard Gamble	
7	179	Mild angina	0.80		Authors	Author/Clinical Judgement	
7	9	Mild chest pain	1.00		Authors	Author/Clinical Judgement	
7	147	Post-myocardial infarction with mild angina, congestive heart failure	0.85		Patients	Time Trade Off	
7	147	Post-myocardial infarction with mild angina, no congestive heart failure	0.89		Patients	Time Trade Off	
7	9	Moderate chest pain	0.90		Authors	Author/Clinical Judgement	
7	6	Moderately severe angina	0.70		Authors	Author/Clinical Judgement	
7	47	NYHA functional class II angina	0.90				
7	5	Severe angina	0.00		Authors	Author/Clinical Judgement	
7	9	Severe chest pain	0.70		Authors	Author/Clinical Judgement	
7	30	Severe angina	0.70				

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	(listed below)						
7	70	Severe angina	0.70		Patients	Time Trade Off, Authors/Clinical Judgement	
7	47	NYHA functional class III/IV angina	0.70				
7	9	Very severe chest pain	0.50		Authors	Author/Clinical Judgement	
7	147	Post-AMI with severe angina, congestive heart failure	0.78		Patients	Time Trade Off	
7	147	Post-AMI with severe angina, no congestive heart failure	0.82		Patients	Time Trade Off	
7	116	Coronary artery disease patients not surviving 10 years, eligible but without medical treatment	0.45				
7	116	Coronary artery disease patients not surviving 10 years with medical treatment	0.50				
7	116	Coronary artery disease patients not surviving 10 years eligible for but without angioplasty	0.50				
7	116	Coronary artery disease patients not surviving 10 years eligible but without angioplasty	0.50				
7	116	Coronary artery disease patients surviving 10 years eligible but without coronary artery bypass	0.60				
7	116	Coronary artery disease patients surviving 10 years eligible for but without angioplasty	0.70				
7	116	Coronary artery disease patients surviving >10 years eligible for but without medical treatment	0.75				
7	116	Coronary artery disease patients surviving >10 years with medical treatment	0.80				
7	6	Improved angina following coronary artery bypass (CABG)	0.85		Authors	Author/Clinical Judgement	
Congestive Heart Failure							
7	203	Congestive heart failure (no angina)	0.801		Patients	Time Trade Off	
7	147	Post-myocardial infarction (MI), with no angina, congestive heart failure	0.89		Patients	Time Trade Off	
7	30	Depressed ventricular function	0.85				
7	90	Congestive heart failure	0.50		Authors	Author/Clinical Judgement	
7	62	Congestive heart failure	0.90	0.8-1			
7	179	Mild to moderate congestive heart failure	0.70		Authors	Author/Clinical Judgement	
7	179	Severe congestive heart failure	0.60		Authors	Author/Clinical Judgement	
7	158	Congestive heart failure usual care	0.46		Community, Patients		EuroQoL

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
7	11	Patients with congestive heart failure before heart transplant	0.20	0.15-0.3	Patients	Standard Gamble, Rating Scale	
7	11	Patients with congestive heart failure after heart transplant	0.70	0.55-0.85	Patients	Standard Gamble, Rating Scale	
7	158	Congestive heart failure epoprostenol treatment	0.50		Community, Patients		EuroQoL
7	108	Living after hospitalization for pulmonary edema	0.70		Community, Clinicians, Patients		Rosser index
Hypertension							
7	2	Side effects of hypertension treatment	0.99		Authors	Author/Clinical Judgement	
7	39	Side effects of antihypertensive medication	0.99	0.98-0.995			Fanshel & Bush, Oper Res 18:1021-66
7	83	Hypertension medications with side effects	0.986		Patients	Time Trade Off	
7	113	Antihypertensive treatment with propranolol	1.00	0.99, 0.995	Authors	Author/Clinical Judgement	
7	113	Treatment with any antihypertensive medication	1.00	0.98	Authors	Author/Clinical Judgement	
7	206	Hypertension treatment	1.00		Clinicians, Authors	Author/Clinical Judgement	
General Cardiac							
7	58	Life 1 year after beginning cardiac rehabilitation program	0.872		Patients	Time Trade Off	
7	59	Severe disability - cardiac	0.10		Authors	Author/Clinical Judgement	
7	59	Moderate disability - cardiac	0.50		Authors	Author/Clinical Judgement	
7	62	Asymptomatic, with or without history of myocardial infarction (MI)	1.00				
Stroke							
7	155	Stroke free	1.00				
7	187	Transient cerebral events (transient ischemic attacks (TIA's) or reversible strokes)	0.80		Authors		
7	20	Neurologic impairment following embolus (stroke)	0.50				

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
7	39	Non-fatal stroke	0.80				Fanshel & Bush, Oper Res 18:1021-66
7	134	After stroke	0.60	0.6-0.8	Patients	Time Trade Off	
7	133	Stroke	0.40	0.08-0.51	Patients	Rating Scale	
7	134	After stroke post-myocardial infarction (MI)	0.54		Patients	Time Trade Off	
7	105	Stroke following myocardial infarction (MI)	0.79	0.5-0.9	Patients	Time Trade Off	
7	76	Stroke	0.50		Authors	Author/Clinical Judgement	
7	84	Life after nonfatal stroke	0.85	0.75-0.95	Authors	Author/Clinical Judgement	
7	193	Stroke with long term morbidity	0.50				
7	210	First stroke	0.54	0.27-1	Patients		
7	210	6 months after 1st stroke	0.77		Patients, Authors	Author/Clinical Judgement	
7	228	Stroke	0.76	0.5-0.9	Authors	Author/Clinical Judgement	
7	184	Nonfatal stroke	0.79		Community		Health Utilities Index (HUI) 1
7	187	Irreversible stroke	0.20		Authors		
7	192	Stroke	0.76		Patients	Time Trade Off	
7	98	Central nervous system (CNS) hemorrhage	0.76	0.5-0.91	Patients	Time Trade Off	
7	206	Stroke compared to same age	0.80		Community		
7	107	Minor stroke	0.75		Authors	Author/Clinical Judgement	
7	155	Minor stroke	0.80	0.64, 0.72, 0.88, 0.96			
7	182	Minor stroke	0.75		Patients	Time Trade Off	
7	169	Minor stroke	0.77		Authors	Author/Clinical Judgement	
7	98	Mild stroke	0.75	0-1	Patients	Time Trade Off	
7	193	Minor stroke, first month only	0.70				
7	182	Moderate stroke	0.39		Patients	Time Trade Off	
7	169	Major stroke	0.39		Patients, Authors	Time Trade Off, Author/Clinical Judgement	
7	155	Major stroke	0.20	0.18, 0.16, 0.22, 0.24			
7	107	Major stroke	0.40	0.2-0.8	Authors	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
7	62	Major stroke	0.50	0-1			
7	182	Major stroke (moderate/severe)	0.30		Patients	Time Trade Off	
7	98	Moderate to severe stroke	0.39	0-1	Patients	Time Trade Off	
7	182	Severe stroke	0.12		Patients	Time Trade Off	
7	84	Hospitalization for side effects or stroke	0.50		Authors	Author/Clinical Judgement	
7	84	Side effects from stroke not requiring hospitalization	0.95		Authors	Author/Clinical Judgement	
7	210	Recurrent stroke	0.29	0.14-0.43	Patients	Rating Scale	
7	98	Recurrent stroke	0.12	0-0.91	Patients	Time Trade Off	
7	169	Recurrent major stroke	0.12		Patients, Authors	Time Trade Off, Author/Clinical Judgement	
7	105	Stroke and reinfarction following myocardial infarction (MI)	0.50		Patients	Time Trade Off	
7	111	Living with an asymptomatic, unruptured, intracranial aneurysm	0.95	0.9-1	Authors	Author/Clinical Judgement	
7	111	Recovery period (3 months) after aneurysm repair with neurological deficit	0.57		Authors	Author/Clinical Judgement	
7	111	Postoperative (aneurysm clipping) or posthemorrhagic neurological deficit	0.76	0.5-1	Authors	Author/Clinical Judgement	
7	228	Complete cerebral aneurysm clipping (cured)	1.00		Authors	Author/Clinical Judgement	
7	228	Partial cerebral aneurysm clipping (at risk for future subarachnoid hemorrhages (SAH))	1.00		Authors	Author/Clinical Judgement	
7	145	Morbidity from treatment for cerebral arteriovenous malformations	0.50		Authors	Author/Clinical Judgement	
Anticoagulation							
7	51	Bleeding event	0.072				
7	60	Short-term morbidity from systemic hemorrhage	0.70		Clinicians	Author/Clinical Judgement	
7	51	Sequelae of bleeding event	0.60				
7	60	Long-term morbidity from systemic hemorrhage	0.50		Clinicians	Author/Clinical Judgement	
7	193	Hemorrhage with long term morbidity	0.60				
7	193	Hemorrhage without long term morbidity, first month	0.90				
7	51	Good health with anticoagulant therapy	0.99				
7	98	Well coumadin to prevent stroke	0.998	0.92-1	Patients	Time Trade Off	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
7	98	Well aspirin to prevent stroke	0.998	0.96-1	Patients Clinicians	Time Trade Off Author/Clinical Judgement	
7	60	Chronic anticoagulation therapy	0.99	<0.92-0.99			
7	20	Prolonged hospital stay with bleeding event death	0.986				
7	20	Prolonged hospital stay with bleeding event resolution	0.989				
7	20	Prolonged hospital stay with bleeding event morbidity	0.943				
Valvular Heart Disease/Thromboembolism							
7	51	Sequelae of thromboembolic event	0.50				
7	51	Thromboembolic event	0.58				
7	20	Prolonged hospital stay with valve thrombotic death	0.885				
7	20	Prolonged hospital stay with thromboembolic morbidity	0.915				
7	20	Prolonged hospital stay surviving valve thrombosis	0.929				
7	20	Prolonged hospital stay with thromboembolic resolution	0.975				
7	20	Prolonged hospital stay with thromboembolic death	0.978				
Deep Vein Thrombosis/Pulmonary Embolus							
7	167	Deep venous thrombosis	0.95		Clinicians	Author/Clinical Judgement	
7	60	Venous thrombosis	0.90		Clinicians	Author/Clinical Judgement	
7	60	Pulmonary embolization	0.60		Clinicians	Author/Clinical Judgement	
7	167	Pulmonary embolism	0.90		Clinicians	Author/Clinical Judgement	
7	167	Fatal pulmonary embolism	0.00		Clinicians	Author/Clinical Judgement	
Peripheral Vascular Disease							
7	103	Leg necrosis	0.21	0-0.69	Community, Clinicians		Health Utilities Index (HUI) 1
7	103	Leg necrosis and major surgical morbidity (cardiovascular,neurological, renal)	0.12	0-0.69	Community, Clinicians		Health Utilities Index (HUI) 1
7	103	Rest pain (leg)	0.33	0-0.69	Community, Clinicians		Health Utilities Index (HUI) 1
7	159	Rest pain/ulceration (leg)	0.35		Community, Clinicians	Time Trade Off, Rating Scale	

Catalog of Preference Scores							
<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
7	103	Rest pain (leg) and major surgical morbidity (cardiovascular,neurological, renal)	0.24	0-0.69	Community, Clinicians		Health Utilities Index (HUI) 1
7	103	Leg claudication	0.57	0.24-0.69	Community, Clinicians		Health Utilities Index (HUI) 1
7	133	Intermittent claudication	0.85	0.9-1	Authors	Author/Clinical Judgement	
7	159	Claudication	0.70		Community, Clinicianshk	Time Trade Off, Rating Scale	
7	103	Claudication and major surgical morbidity (cardiovascular,neurological, renal)	0.26	0-0.69	Community, Clinicians		Health Utilities Index (HUI) 1
7	127	Conventional angiography for peripheral vascular disease (PVD)	0.9985	0.995-1	Authors	Author/Clinical Judgement	
7	127	Blind surgical exploration for peripheral vascular disease (PVD)	0.995		Authors	Author/Clinical Judgement	
7	127	Successful surgical bypass grafting for peripheral vascular disease (PVD)	0.939	0.9-1	Community, Authors		Quality of Well-Being Scale (QWB)
7	127	Repeated surgical procedures for peripheral vascular disease (PVD)	0.98		Authors	Author/Clinical Judgement	
7	108	Living after hospitalization for vascular surgery	0.86		Community, Clinicians, Patients		Rosser index
7	103	Successful treatment of patients with femoropopliteal disease	0.93	0.64-1	Community, Clinicians		Health Utilities Index (HUI) 1
7	103	No peripheral artery disease symptoms but major morbidity (cardiovascular,neurological, renal)	0.30	0-0.92	Community, Clinicians		Health Utilities Index (HUI) 1
7	160	Abdominal aortic aneurysm (AAA) rupture	0.00		Authors	Author/Clinical Judgement	
7	160	Successful abdominal aortic aneurysm (AAA)repair	1.00		Authors	Author/Clinical Judgement	
7	60	Chronic lower-extremity edema	0.90		Clinicians	Author/Clinical Judgement	
8. Diseases of the Respiratory System							
Respiratory Procedures							
8	44	Arterial blood gas (ABG)	0.9997	0.999-1	Authors	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
8	44	Induced sputum	0.9995	0.999-1	Authors	Author/Clinical Judgement	
8	44	Bronchoscopy	0.997	0.995-1	Authors	Author/Clinical Judgement	
Obstructive Airways Disease/Sleep Apnea							
8	108	Living after hospitalization for asthma	0.93		Community, Clinicians, Patients		Rosser index
8	86	Chronic obstructive pulmonary disease (lifelong, high supportive care needs & poor functional status)	0.40	0.2-0.8	Authors	Author/Clinical Judgement	
8	87	Obstructive sleep apnea, pre-treatment	0.63		Patients	Standard Gamble	
8	87	Obstructive sleep apnea, post-treatment with continuous positive airway pressure (CPAP)	0.87		Patients	Standard Gamble	
Lung Transplant							
8	139	Lung transplant waiting list	0.65		Patients	Standard Gamble	
8	139	< 4 months post-lung transplant	0.73		Patients	Standard Gamble	
8	139	> 4 months post-lung transplant	0.89		Patients	Standard Gamble	
8	139	Post-lung transplant	0.80		Patients	Standard Gamble	
9	9. Diseases of the Digestive System						
GI Bleed							
9	210	Gastrointestinal bleeding	0.54	0.49-0.54	Authors	Author/Clinical Judgement, Rating Scale	
9	216	Variceal hemorrhage	0.28	0.14-0.65	Clinicians	Time Trade Off, Rating Scale	
9	194	Recurrent episodes of variceal bleeding	0.70		Authors		
Gallbladder							
9	31	Acute cholecystitis	0.77	0.45-1	Clinicians	Rating Scale	
9	31	Biliary colic	0.97	0.5-1	Clinicians	Rating Scale	
9	227	Moderate (chest and back) pain relating to gallbladder	0.90		Community	Time Trade Off	
9	227	Severe (chest and back) pain relating to gallbladder (periodically)	0.88		Community	Time Trade Off	
9	227	Moderate (chest and back) pain relating to gallbladder/severe diarrhea	0.68		Community	Time Trade Off	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
9	227	Severe (chest and back) pain relating to gallbladder /severe diarrhea/nausea	0.47		Community Authors	Time Trade Off Author/Clinical Judgement	
9	29	Symptoms/chronic pain from gallstones	0.95	0.90-1.0			
9	31	Persistent gallstone	0.99	0.5-1	Clinicians	Rating Scale	
9	31	Bile salt medication	0.97	0.5-1	Clinicians	Rating Scale	
9	48	Postcholecystectomy syndrome	0.79		Patients	Standard Gamble	
9	31	Postcholecystectomy syndrome	0.95	0.5-1	Clinicians	Rating Scale	
		Hepatitis					
9	215	Hepatitis A	0.917		Authors	Author/Clinical Judgement	
9	67	Symptomatic acute hepatitis	0.96	0.92-0.98	Clinicians, Authors	Author/Clinical Judgement	
9	49	Symptomatic acute hepatitis	0.962	0.923-0.981	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
9	178	Symptoms of acute hepatitis	0.9615				
9	49	Hospitalization for acute hepatitis	0.981	0.962-0.99	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
9	67	Hospitalization for acute hepatitis	0.98	0.98-0.99	Clinicians, Authors	Author/Clinical Judgement	
9	178	Hospitalization for acute hepatitis	0.9808				
9	97	Fulminant hepatitis	0.00		Authors	Author/Clinical Judgement	
9	178	Asymptomatic chronic hepatitis B or C	0.99				
9	49	Asymptomatic chronic hepatitis	0.99	0.95-1.0	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
9	67	Asymptomatic chronic hepatitis	0.99	0.95-1	Clinicians, Authors	Author/Clinical Judgement	
9	126	HBsAg+ & HBeAg-	0.99	0.97-1	Clinicians	Standard Gamble, Time Trade Off	
9	97	Active hepatitis	0.90		Authors	Author/Clinical Judgement	
9	49	Symptomatic chronic hepatitis	0.90	0.75-0.95	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
9	67	Symptomatic chronic hepatitis	0.90	0.75-0.95	Clinicians, Authors	Author/Clinical Judgement	
9	178	Symptomatic chronic hepatitis B or C	0.90				
9	94	Chronic hepatitis	0.80		Clinicians	Author/Clinical Judgement	
9	126	Chronic hepatitis	0.94	0.85-1	Clinicians	Standard Gamble, Time Trade Off	
9	209	Chronic hepatitis	0.95		Clinicians	Author/Clinical Judgement	
9	216	Mild chronic hepatitis	0.82	0.63-0.98	Clinicians	Time Trade Off, Rating Scale	
9	216	Moderate chronic hepatitis	0.78	0.60-0.90	Clinicians	Time Trade Off, Rating Scale	
9	126	HBsAg+ & HBeAg+	0.95	0.84-1	Clinicians	Standard Gamble, Time Trade Off	
9	97	Persistent hepatitis	0.99		Authors	Author/Clinical Judgement	
9	49	Interferon therapy for hepatitis	0.962	0.923-0.981	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
9	67	Interferon therapy for hepatitis	0.96	0.92-0.98	Clinicians, Authors	Author/Clinical Judgement	
9	178	Interferon therapy for hepatitis	0.9615				
9	216	Interferon-alpha-2b treatment for hepatitis	0.93	0.90-1.00	Clinicians	Time Trade Off, Rating Scale	
9	126	Interferon treatment for hepatitis B	0.9615	0.9231-1	Clinicians	Standard Gamble, Time Trade Off	
9	94	Resolved hepatitis after interferon treatment	0.90		Clinicians	Author/Clinical Judgement	
Cirrhosis + Sequelae							
9	94	Cirrhosis	0.50		Clinicians	Author/Clinical Judgement	
9	90	Presence of cirrhosis	0.80		Authors	Author/Clinical Judgement	
9	209	Compensated cirrhosis	0.80		Clinicians	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference # (listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
9	126	Compensated cirrhosis	0.92	0.83-1	Clinicians	Standard Gamble, Time Trade Off	
9	216	Compensated cirrhosis	0.70	0.50-0.90	Clinicians	Time Trade Off, Rating Scale	
9	126	Decompensated cirrhosis	0.54	0.13-0.95	Clinicians	Standard Gamble, Time Trade Off	
9	209	Decompensated cirrhosis	0.50		Clinicians	Author/Clinical Judgement	
9	216	Hepatic encephalopathy	0.30	0.07-0.75	Clinicians	Time Trade Off, Rating Scale	
9	194	No variceal bleeding with mild-moderate mental impairment from hepatic encephalopathy secondary to shunt surgery	0.90		Authors		
9	194	No variceal bleeding with severe mental impairment from hepatic encephalopathy secondary to shunt surgery	0.20		Authors		
9	216	Ascites	0.35	0.11-0.88	Clinicians	Time Trade Off, Rating Scale	
9	97	Cirrhosis or liver cancer	0.90		Authors	Author/Clinical Judgement	
9	77	Cirrhosis/acute/chronic active hepatitis with functioning transplant	0.41	0.35-0.6	Authors	Author/Clinical Judgement	
9	90	Cirrhosis, diabetes, & heart failure	0.70		Authors	Author/Clinical Judgement	
9	90	Cirrhosis & diabetes	0.72		Authors	Author/Clinical Judgement	
9	90	Cirrhosis & heart failure	0.78		Authors	Author/Clinical Judgement	
9	194	No variceal bleeding (VB) with minor propranolol side effects	0.98		Authors		
9	194	No variceal bleeding (VB) or any treatment complications	1.00		Authors		
9	194	No variceal bleeding (VB) with esophageal stricture from sclerotherapy	0.95		Authors		
General Liver							
9	115	Chronic liver disease	0.60		Authors	Author/Clinical Judgement	
9	94	Severe liver disease	0.20		Clinicians	Author/Clinical Judgement	
9	216	Liver transplantation, 1st yr.	0.50	0.11-0.70	Clinicians	Time Trade Off, Rating Scale	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
9	216	Liver transplantation, after 1st yr.	0.70	0.24-0.87	Clinicians	Time Trade Off, Rating Scale	
9	209	Time after liver transplant	0.80		Clinicians	Author/Clinical Judgement	
9	77	Chronic liver disease on kidney dialysis	0.36	0-0.36	Authors	Author/Clinical Judgement	
Pancreas							
9	31	Biliary pancreatitis	0.90	0.5-1	Clinicians	Rating Scale	
9	138	Recurrent pancreatitis	0.808		Clinicians	Time Trade Off	
9	138	Pancreatitis if stone present	0.9712		Clinicians	Time Trade Off	
Nausea, Vomiting, and Bowel							
9	8	Nausea & diarrhea for 5 days	0.9863		Community		Quality of Well-Being Scale (QWB)
9	88	Utility improvement from more effective antiemetic therapy	0.20		Authors	Author/Clinical Judgement	
9	156	Gastrointestinal adverse event during treatment of Acute Otitis Media	0.70	0.608-0.792	Clinicians	Rating Scale	
9	171	Drug rash or diarrhea (7days) from antibiotics to treat Helicobacter pylori	0.995	0.9-0.999	Community		Quality of Well-Being Scale (QWB)
9	227	Severe diarrhea	0.81		Community	Time Trade Off	
9	196	Crohn's relapse requiring hospitalization with surgical intervention	0.50		Clinicians	Author/Clinical Judgement	
9	196	Crohn's relapse requiring hospitalization without surgical intervention	0.55		Clinicians	Author/Clinical Judgement	
9	196	Crohn's relapse not requiring hospitalization	0.60		Clinicians	Author/Clinical Judgement	
9	196	Remission of operated Crohn's	0.85	0.79-0.88	Clinicians	Author/Clinical Judgement	
9	196	Remission of non-operated Crohn's	0.90		Clinicians	Author/Clinical Judgement	
9	8	Abdominal pain for 5 days	0.9863		Community		Quality of Well-Being Scale (QWB)
Esophagus and Stomach							
9	175	Reflux symptoms	0.82	0.5-0.95	Clinicians		
9	175	Omeprazole chronic use	1.00	0.98-1	Authors	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
9	193	Esophageal perforation, first month	0.90				
9	85	Living with esophagectomy	0.80	0-1	Authors	Author/Clinical Judgement	
9	171	Inpatient treatment of complicated gastrointestinal ulcer (7 days)	0.99	0.9-0.995	Community		Quality of Well-Being Scale (QWB)
GI Procedures and Surgeries							
9	171	Experiencing an upper gastrointestinal barium study	0.999	0.9-1	Community		Quality of Well-Being Scale (QWB)
9	85	Esophageal endoscopy with complication	0.9808		Clinicians	Author/Clinical Judgement	
9	85	Esophageal endoscopy	0.9973		Clinicians	Author/Clinical Judgement	
9	171	Experiencing upper endoscopy	0.999	0.9-1	Community		Quality of Well-Being Scale (QWB)
9	175	Anti-gastrointestinal reflux surgery, short term	0.50		Authors	Author/Clinical Judgement	
9	175	Anti-gastrointestinal reflux surgery, long term	1.00	0.9-1	Authors	Author/Clinical Judgement	
9	85	Emergency surgery for Barrett's esophagus	0.9233		Clinicians	Author/Clinical Judgement	
9	85	Elective surgery for Barrett's esophagus	0.9616		Clinicians	Author/Clinical Judgement	
9	171	Inpatient treatment of a complicated gastrointestinal ulcer with surgery (4 days intensive care, 10 days hospital)	0.979	0.9-0.99	Community		Quality of Well-Being Scale (QWB)
9	138	Endoscopic retrograde cholangiogram (ERCP) procedure alone	0.9904		Clinicians	Time Trade Off	
9	31	Endoscopic sphincterotomy	0.90	0.5-1	Clinicians	Rating Scale	
9	48	Endoscopic sphincterectomy	0.95		Patients	Standard Gamble	
9	138	Endoscopic retrograde cholangiogram (ERCP) complication	0.808		Clinicians	Time Trade Off	
9	138	Papillotomy complication	0.7115		Clinicians	Time Trade Off	
9	49	Liver biopsy	0.995	0.981-0.997	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
9	178	Liver biopsy	0.9945				
9	67	Liver biopsy	0.9945	0.98-0.9973	Clinicians, Authorsj	Author/Clinical Judgement	
9	31	Extracorporeal shock-wave lithotripsy (ESWL) procedure for gallstones	0.95	0.5-1	Clinicians	Rating Scale	
9	31	Complication of extracorporeal shockwave lithotripsy (ESWL) for gallstones	0.89	0.5-1	Clinicians	Rating Scale	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
9	31	T-tube extraction of gallstone	0.94	0.5-1	Clinicians	Rating Scale	
9	48	T-tube extraction of gallbladder stone	0.83		Patients	Standard Gamble	
9	48	Laparoscopic cholecystectomy	0.91		Patients	Standard Gamble	
9	227	Laparoscopic cholecystectomy (normal)	0.90		Community	Time Trade Off	
9	227	Open cholecystectomy (normal)	0.81		Community	Time Trade Off	
9	48	Open cholecystectomy	0.77		Patients	Standard Gamble	
9	31	Open cholecystectomy	0.73	0.4-1	Clinicians	Rating Scale	
9	31	Scar from gallbladder surgery	0.993	0.5-1	Clinicians	Rating Scale	
9	48	Scar from gallbladder surgery	0.998		Patients	Standard Gamble	
9	31	Complication from gallbladder surgery	0.92	0.5-1	Clinicians	Rating Scale	
9	48	Complication of cholecystectomy	0.77		Patients	Standard Gamble	
9	31	Biliary stricture surgery	0.52	0.2-1	Clinicians	Rating Scale	
9	48	Biliary stricture surgery	0.64		Patients	Standard Gamble	
9	48	Reexploration of biliary tree	0.77		Patients	Standard Gamble	
9	31	Reexploration of biliary tree	0.67	0.35-1	Clinicians	Rating Scale	
9	20	Short-bowel syndrome following bowel resection for embolus	0.50				
9	29	Time spent in hospital for gallstone treatment	0.50		Authors	Author/Clinical Judgement	
9	29	Time spent at home recovering from cholecystectomy	0.70		Authors	Author/Clinical Judgement	
9	108	Living after hospitalization for general surgery	0.85		Community, Clinicians, Patients		Rosser index
9	166	Inpatient treatment of open appendectomy wound, infected, or both	0.60		Authors	Author/Clinical Judgement	
9	166	Outpatient treatment of open appendectomy wound, infected, or both	0.70		Authors	Author/Clinical Judgement	
9	166	Perfectly closed primary or delayed primary appendectomy wound	1.00		Authors	Author/Clinical Judgement	
10		10. Diseases of the Genitourinary System					
		Renal Failure					
10	112	End-stage renal disease (ESRD)	0.59		Patients	Author/Clinical Judgement, Rating Scale	
10	56	End-stage renal disease (ESRD)	0.61				

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	(listed below)						
10	109	End stage renal failure	0.567		Clinicians	Time Trade Off	
10	128	End-stage renal disease (ESRD) due to diabetes	0.61				
10	76	Chronic renal failure	0.60		Authors	Author/Clinical Judgement	
10	112	Progressive renal failure	0.74		Community, Authors		Quality of Well-Being Scale (QWB)
10	109	Angiotensin converting enzyme inhibition to prevent nephropathy	0.826	0.814-0.838	Clinicians	Time Trade Off	
Kidney Dialysis							
10	16	Hospital dialysis	0.50		Authors	Author/Clinical Judgement	
10	77	Dialysis	0.41	0.41-0.56	Patients	Time Trade Off	
10	207	Dialysis pre kidney transplant	0.68	0.55-0.85			
10	207	Dialysis <6 months after failed first or repeat kidney transplant	0.65	0.4-0.75			
10	207	Dialysis >=6months after failed first or repeat kidney transplant	0.68	0.4-0.75			
10	16	Home dialysis	0.60		Authors	Author/Clinical Judgement	
10	220	Renal patients pre kidney transplant	0.57		Patients	Time Trade Off	
Kidney Transplant							
10	16	Functioning renal transplant graft	0.90		Authors	Author/Clinical Judgement	
10	77	Functioning kidney transplant	0.74	0.6-0.85	Patients	Time Trade Off	
10	139	Diabetic with kidney transplantation alone	0.80	0.75-0.85	Authors	Author/Clinical Judgement	
10	207	Successful first or repeat kidney transplant	0.84	0.75-0.95			
10	220	1 month post renal transplant	0.68		Patients	Time Trade Off	
10	220	3 months post renal transplant	0.71		Patients	Time Trade Off	
10	220	6 months post renal transplant	0.75		Patients	Time Trade Off	
10	220	12 months post renal transplant	0.74		Patients	Time Trade Off	
10	220	18 months post renal transplant	0.70		Patients	Time Trade Off	
10	220	24 months post renal transplant	0.70		Patients	Time Trade Off	
10	139	Diabetic with simultaneous pancreas-kidney transplantation	0.90		Authors	Author/Clinical Judgement	
Genitourinary Symptoms							
10	40	Survive after penile problems (1st year only)	0.99	0-1	Authors	Author/Clinical Judgement	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
10	129	Symptoms of mild prostatism	0.99		Community, Authors		Health Utilities Index (HUI) 2
10	129	Symptoms of mild prostatism along with stress incontinence	0.75		Community, Authors		Health Utilities Index (HUI) 2
10	129	Symptoms of mild prostatism along with impotence	0.86		Community, Authors		Health Utilities Index (HUI) 2
10	129	Symptoms of moderate prostatism	0.90		Community, Authors		Health Utilities Index (HUI) 2
10	78	Urethral obstruction (moderate to severe)	0.80		Clinicians	Time Trade Off	
10	129	Symptoms of severe prostatism	0.79		Community, Authors		Health Utilities Index (HUI) 2
10	78	Partial incontinence	0.81	0.71-0.91	Clinicians	Time Trade Off	
10	149	Incontinence	0.85	0.6-1	Clinicians		
10	78	Complete incontinence	0.61	0.51-0.71	Clinicians	Time Trade Off	
10	129	Total urinary incompetence following transurethral resection of the prostate (TURP)	0.70		Community, Authors		Health Utilities Index (HUI) 2
10	78	Partial impotence	0.85	0.75-0.95	Clinicians	Time Trade Off	
10	149	Impotence	0.95	0.8-1	Clinicians		
10	78	Complete impotence	0.92		Clinicians	Time Trade Off	
10	223	Serious complications (incontinence/impotence) following prostate surgery	0.73	0-1	Authors	Author/Clinical Judgement	
10	137	Prostate cancer surgery complications (incontinence, impotence, and gastrointestinal problems)	0.80	<0.8	Authors	Author/Clinical Judgement	
10	223	Two serious complications (incontinence + impotence) following prostate surgeries	0.50	0-1	Authors	Author/Clinical Judgement	
10	165	Pyelonephritis	0.6268		Community		Quality of Well-Being Scale (QWB)
10	165	Vaginitis	0.7106		Community		Quality of Well-Being Scale (QWB)
10	165	Persistent dysuria	0.7106		Community		Quality of Well-Being Scale (QWB)
10	165	Other side effects from antibiotics (e.g. rash/diarrhea) for urine infection	0.7106		Community		Quality of Well-Being Scale (QWB)
10	165	Office visit for urine infection	0.90		Community		Quality of Well-Being Scale (QWB)
10	165	Antibiotic treatment for urine infection	0.99		Community		Quality of Well-Being Scale (QWB)

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
12. Diseases of the Skin and Subcutaneous Tissue							
General Skin							
12	156	Dermatologic adverse event during treatment of Acute Otitis Media	0.77	0.694-0.846	Clinicians	Rating Scale	
12	95	In hospital related to diabetic foot ulcer treatment	0.50		Clinicians	Author/Clinical Judgement	
12	95	Diabetic foot ulcer	0.79		Clinicians	Author/Clinical Judgement	
12	95	Postoperative disability relating to diabetic foot ulcer treatment	0.85		Clinicians	Author/Clinical Judgement	
Chiropody							
12	33	60-75 year old domiciliary patients needing routine chiropody services	0.949		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old domiciliary patients needing special chiropody services	0.938		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old clinic patients needing routine chiropody services	0.986		Community, Clinicians, Patients		Rosser index
12	33	60-75 yo clinic patients needing special chiropody services	0.956		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old domiciliary patients without routine chiropody services	0.906		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old domiciliary patients without special chiropody services	0.885		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old clinic patients without routine chiropody services	0.973		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old clinic patients without special chiropody services	0.942		Community, Clinicians, Patients		Rosser index

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	(listed below)						
12	33	60-75 year old domiciliary patients after routine chiropody services	0.968		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old domiciliary patients after special chiropody services	0.956		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old clinic patients after routine chiropody services	1.00		Community, Clinicians, Patients		Rosser index
12	33	60-75 year old clinic patients after special chiropody services	0.986		Community, Clinicians, Patients		Rosser index
12	33	>75 year old domiciliary patients needing routine chiropody services	0.938		Community, Clinicians, Patients		Rosser index
12	33	>75 year old domiciliary patients needing special chiropody services	0.942		Community, Clinicians, Patients		Rosser index
12	33	>75 year old clinic patients needing routine chiropody services	0.973		Community, Clinicians, Patients		Rosser index
12	33	>75 year old clinic patients needing special chiropody services	0.956		Community, Clinicians, Patients		Rosser index
12	33	>75 year old domiciliary patients without routine chiropody services	0.885		Community, Clinicians, Patients		Rosser index
12	33	>75 year old domiciliary patients without special chiropody services	0.70		Community, Clinicians, Patients		Rosser index
12	33	>75 year old clinic patients without routine chiropody services	0.942		Community, Clinicians, Patients		Rosser index
12	33	>75 year old clinic patients without special chiropody services	0.912		Community, Clinicians, Patients		Rosser index

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	(listed below)						
12	33	>75 year old domiciliary patients after routine chiropody services	0.96		Community, Clinicians, Patients		Rosser index
12	33	>75 year old domiciliary patients after special chiropody services	0.956		Community, Clinicians, Patients		Rosser index
12	33	>75 year old clinic patients after special chiropody services	0.986		Community, Clinicians, Patients		Rosser index
12	33	>75 year old clinic patients after routine chiropody services	0.99		Community, Clinicians, Patients		Rosser index
13		13. Diseases of the Musculoskeletal System and Connective Tissue					
		Upper Extremity					
13	144	1st year after forearm & shoulder fractures	0.95				
13	104	Forearm or shoulder fracture (first year)	0.95				
13	142	Patient needing flexor tenosynovectomy	0.846		Community, Clinicians, Patients		Rosser index
13	142	Patient after flexor tenosynovectomy	0.881		Community, Clinicians, Patients		Rosser index
13	142	Patient needing operation for Dupuytren's contracture	0.981		Community, Clinicians, Patients		Rosser index
13	142	Patient after operation for Dupuytren's contracture	0.994		Community, Clinicians, Patients		Rosser index
13	142	Patient needing operation for carpal tunnel syndrome	0.951		Community, Clinicians, Patients		Rosser index

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
13	142	Patient after operation for carpal tunnel syndrome	0.964		Community, Clinicians, Patients		Rosser index
13	142	Patient needing metacarpophalangeal joint replacement	0.918		Community, Clinicians, Patients		Rosser index
13	142	Patient after metacarpophalangeal joint replacement	0.954		Community, Clinicians, Patients		Rosser index
Hip							
17	3	Hip fracture	0.95				
17	26	Acute uncomplicated hip fracture	0.95				
17	28	Acute uncomplicated hip fracture	0.95		Authors		
13	26	Post-hip fracture well	1.00				
13	28	Post-hip fracture recovered	1.00		Authors		
13	26	Disability following hip fracture	0.80				
13	28	Hip fracture disabled but independent living	0.80		Authors		
13	72	Post hip fracture living at home	0.90	0.67, 0.9	Authors	Author/Clinical Judgement	
13	144	Severely handicapped after hip fracture	0.40	0.35-0.85			
13	104	Severely handicapped in years after hip fracture	0.40	0.35-0.85			
13	27	Hip fracture-nursing home	0.40				
13	26	Long-term nursing home placement after hip fracture	0.40				
13	72	Post hip fracture living at nursing home	0.67	0.67, 0.9	Authors	Author/Clinical Judgement	
13	104	First year after hip fracture	0.80	0.56-0.83			
13	144	First year after hip fracture	0.80	0.56-0.83			
13	104	Near-normal functioning in years after hip fracture	0.90	0.90-0.99			
13	144	Return to near-normal functioning after hip fracture	0.90	0.90-0.99			
13	132	American College of Rheumatology (ACR) Functional Class I for hip osteoarthritis	1.00		Community	Standard Gamble	
13	132	American College of Rheumatology (ACR) Functional Class II for hip osteoarthritis	0.80		Community	Standard Gamble	
13	132	American College of Rheumatology (ACR) Functional Class III for hip osteoarthritis	0.50		Community	Standard Gamble	
13	132	American College of Rheumatology (ACR) Functional Class IV for hip osteoarthritis	0.30		Community	Standard Gamble	
13	80	Prior to elective hip surgery with osteoarthritis	0.29		Patients	Time Trade Off	

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
13	142	Patient needing primary hip replacement	0.892		Community, Clinicians, Patients		Rosser index
13	142	Patient needing revision hip replacement	0.80		Community, Clinicians, Patients		Rosser index
13	80	3 months post elective hip surgery with osteoarthritis	0.84		Patients	Time Trade Off	
13	142	Patient after primary hip replacement	0.976		Community, Clinicians, Patients		Rosser index
13	201	Living with total hip or knee replacement without infection	0.658	0.38-0.95			
13	142	Patient after revision hip replacement	0.976		Community, Clinicians, Patients		Rosser index
13	201	Resolved total hip or knee replacement infection, with amputation	0.35	0.2-0.8			
13	201	Resolved total hip or knee replacement infection, with joint saved	0.508	0.33-0.58			
13	201	Resolved total hip or knee replacement infection, with joint lost	0.62	0.25-0.7			
Knee and Foot							
13	142	Patient needing primary knee replacement	0.868		Community, Clinicians, Patients		Rosser index
13	212	Preoperative knee arthroplasty	0.56		Community		Quality of Well-Being Scale (QWB)
13	142	Patient after primary knee replacement	0.932		Community, Clinicians, Patients		Rosser index
13	212	3 months post knee arthroplasty	0.56		Community		Quality of Well-Being Scale (QWB)
13	212	6 months post knee arthroplasty	0.59		Community		Quality of Well-Being Scale (QWB)
13	212	1 year post knee arthroplasty	0.59		Community		Quality of Well-Being Scale (QWB)
13	212	2 year post knee arthroplasty	0.59		Community		Quality of Well-Being Scale (QWB)
13	142	Patient needing metatarsal joint procedures	0.939		Community, Clinicians, Patients		Rosser index

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
13	142	Patient after metatarsal joint procedures	0.917		Community, Clinicians, Patients		Rosser index
Spine							
13	3	Spinal compression fracture	0.99				
13	104	Vertebral fracture (first year)	0.90				
13	144	1st year after vertebral fracture	0.90				
13	79	Success after treatment for lumbar disc herniation	0.987		Community, Clinicians, Patients		Rosser index
13	79	Failure after treatment for lumbar disc herniation	0.807		Community, Clinicians, Patients		Rosser index
13	142	Patient needing spine discectomy	0.812		Community, Clinicians, Patients		Rosser index
13	142	Patient after spine discectomy	0.949		Community, Clinicians, Patients		Rosser index
13	152	Treatment for back pain with unsatisfactory outcome	0.56		Clinicians, Patientsh	Time Trade Off	
13	152	Treatment for back pain with satisfactory outcome	0.89		Clinicians, Patientsh	Time Trade Off	
13	202	Thoracic/higher lumbar lesion child	0.454		Community		Quality of Well-Being Scale (QWB)
13	202	Thoracic/higher lumbar lesion adolescent	0.462		Community		Quality of Well-Being Scale (QWB)
13	202	Thoracic/higher lumbar lesion adult	0.465		Community		Quality of Well-Being Scale (QWB)
13	202	Lower lumbar lesion child	0.511		Community		Quality of Well-Being Scale (QWB)
13	202	Lower lumbar lesion adult	0.514		Community		Quality of Well-Being Scale (QWB)
13	202	Lower lumbar lesion adolescent	0.529		Community		Quality of Well-Being Scale (QWB)
13	202	Sacral lesion adult	0.564		Community		Quality of Well-Being Scale (QWB)

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
13	202	Sacral lesion adolescent	0.60		Community		Quality of Well-Being Scale (QWB)
13	202	Sacral lesion child	0.601		Community		Quality of Well-Being Scale (QWB)
Muscle							
13	67	Myelopathy from HTLV	0.50	0.25-1	Clinicians, Authors	Author/Clinical Judgement	
13	49	Myelopathy from HTLV	0.50	0.25-1.0	Clinicians, Authors, Dec. Analysts	Author/Clinical Judgement	
13	97	Adult t-cell lymphoma or HTLV associated myelopathy	0.90		Authors	Author/Clinical Judgement	
13	178	HTLV I/II myelopathy	0.90				
13	136	Fibromyalgia waiting list	0.78	0.47	Patients	Standard Gamble, Rating Scale	
13	136	Fibromyalgia educational intervention	0.80	0.45	Patients	Standard Gamble, Rating Scale	
13	136	Fibromyalgia -cognitive intervention	0.83	0.46	Patients	Standard Gamble, Rating Scale	
Amputation							
13	95	Life after amputation of toe	0.99		Clinicians	Author/Clinical Judgement	
13	95	Transmetatarsal amputation	0.95		Clinicians	Author/Clinical Judgement	
13	159	Below knee amputation	0.61		Community, Clinicians	Time Trade Off, Rating Scale	
13	95	Below Knee Amputation	0.80		Clinicians	Author/Clinical Judgement	
13	56	Lower extremity amputation	0.80				
13	103	Amputation (leg)	0.19	0-0.58	Community, Clinicians		Health Utilities Index (HUI) 1
13	103	Leg amputation and major morbidity from peripheral artery disease	0.03	0-0.58	Community, Clinicians		Health Utilities Index (HUI) 1
13	127	Amputation for peripheral vascular disease	0.484	0.3-0.7	Community, Authors		Quality of Well-Being Scale (QWB)
13	128	Lower extremity amputation due to diabetes	0.80				

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
13	20	Limb amputation following embolus	0.80				
13	159	Above knee amputation	0.20		Community, Clinicians	Time Trade Off, Rating Scale	
General Musculoskeletal							
13	15	Exercise-related injuries	0.90		Authors	Author/Clinical Judgement	
13	19	Morbidity from an artificial-joint infection requiring hospitalization	0.90	0-1.0	Authors	Author/Clinical Judgement	
13	172	Lyme arthritis (symptoms lasting 1 month)	0.95		Clinicians		
17. Injury and Poisoning							
Poisoning							
17	100	Penicillamine chelation	0.971	0.945-1	Authors	Author/Clinical Judgement	
17	100	Penicillamine minor toxicity	0.9993	0.9932-1	Authors	Author/Clinical Judgement	
17	100	Penicillamine major toxicity	0.9979	0.981-1	Authors	Author/Clinical Judgement	
17	100	Penicillamine severe toxicity/death	0.00		Authors	Author/Clinical Judgement	
17	100	EDTA chelation	0.986	0.973-1	Authors	Author/Clinical Judgement	
17	100	EDTA provocation test	0.997	0.9945-1	Authors	Author/Clinical Judgement	
Trauma							
17	173	MAIS (Maximum abbreviated injury scale) 2	0.71	0.5-0.92	Community, Clinicians, Patients		Functional Capacity Index (FCI)
17	173	MAIS (Maximum abbreviated injury scale) 3	0.67	0.47-0.87	Community, Clinicians, Patients		Functional Capacity Index (FCI)
17	173	MAIS (Maximum abbreviated injury scale) 4	0.51	0.36-0.66	Community, Clinicians, Patients		Functional Capacity Index (FCI)

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
17	173	MAIS (Maximum abbreviated injury scale) 5	0.06	0.04-0.08	Community, Clinicians, Patients		Functional Capacity Index (FCI)
17	108	Living after hospitalization for trauma	0.96		Community, Clinicians, Patients		Rosser index
17	131	Perioperative complications for blunt thoracic aortic trauma	0.98		Authors	Author/Clinical Judgement	
General Disability							
18	4	Disability in bed	0.40	0.16, 0.63			
18	4	Disability out of bed	0.60	0.36, 0.77			
18	17	Moderate disability	0.50		Authors	Author/Clinical Judgement	
18	23	Moderate disability - physical	0.50		Authors	Author/Clinical Judgement	
18	23	Severe disability - physical	0.00		Authors	Author/Clinical Judgement	
18	17	Severe disability	0.10		Authors	Author/Clinical Judgement	
General Health							
18	206	General population 35-39 years	0.86		Community	Rating Scale	
18	206	General population 50-64 years	0.82		Community	Rating Scale	
18	208	General population age 65-69	0.76		Community		Years of Health Life Index (YHL)
18	206	General population 65-74 years	0.78		Community	Rating Scale	
18	208	General population age 70-74	0.74		Community		Years of Health Life Index (YHL)
18	206	General population over 75 years	0.71		Community	Rating Scale	
18	208	General population age 75-79	0.70		Community		Years of Health Life Index (YHL)
18	208	General population age 80-84	0.63		Community		Years of Health Life Index (YHL)
18	208	General population age >=85	0.51		Community		Years of Health Life Index (YHL)
18	135	Women 25-29 quit smoking > 15 years	0.92				
18	135	Men 25-29 quit smoking > 15 years	0.93				

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
18	135	Women 30-34 quit smoking > 15 years	0.90				
18	135	Men 30-34 quit smoking > 15 years	0.93				
18	135	Women 35-39 quit smoking > 15 years	0.89				
18	135	Men 35-39 quit smoking > 15 years	0.92				
18	135	Women 40-44 quit smoking > 15 years	0.87				
18	135	Men 40-44 quit smoking > 15 years	0.90				
18	135	Women 45-49 quit smoking > 15 years	0.86				
18	135	Men 45-49 quit smoking > 15 years	0.89				
18	135	Women 50-54 quit smoking > 15 years	0.84				
18	135	Men 50-54 quit smoking > 15 years	0.87				
18	135	Men 55-59 quit smoking > 15 years	0.85				
18	135	Women 55-59 quit smoking > 15 years	0.82				
18	135	Women 60-64 quit smoking > 15 years	0.79				
18	135	Men 60-64 quit smoking > 15 years	0.83				
18	135	Women 65-69 quit smoking > 15 years	0.77				
18	135	Men 65-69 quit smoking > 15 years	0.80				
18	189	Average health of homosexual male cohort	0.90				
18	219	Good health with no breast cancer age 45-54	0.85		Community, Patients	Time Trade Off	
18	219	Poor health with no breast cancer age 45-54	0.29		Community, Patients	Time Trade Off	
18	219	Good health with no breast cancer age 55-64	0.77		Community, Patients	Time Trade Off	
18	219	Poor health with no breast cancer age 55-64	0.35		Community, Patients	Time Trade Off	
18	219	Good health with no breast cancer age 65-69	0.64		Community, Patients	Time Trade Off	
18	219	Poor health with no breast cancer age 65-69	0.24		Community, Patients	Time Trade Off	
		General Health - Smokers					
18	135	Women 25-29 Smokers	0.89				
18	135	Men 25-29 Smokers	0.91				
18	135	Women 30-34 Smokers	0.87				
18	135	Men 30-34 Smokers	0.88				
18	135	Women 35-39 Smokers	0.84				
18	135	Men 35-39 Smokers	0.86				
18	135	Women 40-44 Smokers	0.82				

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
18	135	Men 40-44 Smokers	0.83				
18	135	Women 45-49 Smokers	0.80				
18	135	Men 45-49 Smokers	0.81				
18	135	Women 50-54 Smokers	0.78				
18	135	Men 50-54 Smokers	0.78				
18	135	Women 55-59 Smokers	0.76				
18	135	Men 55-59 Smokers	0.76				
18	135	Women 60-64 Smokers	0.74				
18	135	Men 60-64 Smokers	0.74				
18	135	Women 65-69 Smokers	0.72				
18	135	Men 65-69 Smokers	0.71				
		General Medical Illness					
18	108	Living after hospitalization for general medical diagnoses	0.93		Community, Clinicians, Patients		Rosser index
18	108	Post-treatment for patients with ICU APACHE II score 0-4	0.96		Community, Clinicians, Patients		Rosser index
18	108	Post-treatment for patients with ICU APACHE II score 5-9	0.90		Community, Clinicians, Patients		Rosser index
18	108	Post-treatment for patients with ICU APACHE II score 10-14	0.89		Community, Clinicians, Patients		Rosser index
18	108	Post-treatment for patients with ICU APACHE II score 15-19	0.89		Community, Clinicians, Patients		Rosser index
18	108	Post-treatment for patients with ICU APACHE II score 20-24	0.89		Community, Clinicians, Patients		Rosser index
18	108	Post-treatment for patients with ICU APACHE II score 25-29	0.84		Community, Clinicians, Patients		Rosser index
18	108	Post-treatment for patients with ICU APACHE II score 30-34	0.84		Community, Clinicians, Patients		Rosser index

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
18	108	Post-treatment for patients with ICU APACHE II score 35+	0.85		Community, Clinicians, Patients		Rosser index
18	174	Life after serious illness which dialysis was needed	0.84	0.5-1	Patients	Time Trade Off	
18	184	People without neurological disease but with previous neurologic symptoms	0.94	0.94-1	Community		Health Utilities Index (HUI) 1
References:							
(Note: Only the first three authors are listed for each reference.)							
1	Zeckhauser R, Shepard D. Where now for saving lives? <i>Law Contemporary Problems</i> 1976;40(4): 4-45.						
2	Stason WB, Weinstein MC. Allocation of resources to manage hypertension. <i>N Engl J Med</i> 1977;296(13):732-739.						
3	Weinstein MC. Estrogen use in postmenopausal women: Costs, risks, and benefits. <i>N Engl J Med</i> 1980;303(6):308-316.						
4	Willems JS, Sanders CR, Riddiough MA. Cost-effectiveness of vaccination against pneumococcal pneumonia. <i>N Engl J Med</i> 1980;303(10):553-559.						
5	Pliskin JS, Stason WB, Weinstein MC. Coronary artery bypass graft surgery: clinical decision making and cost-effective analysis. <i>Med Decis Making</i> 1981;1(1):10-28.						
6	Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass graft surgery. <i>Circulation</i> 1982;66(5 pt. 2):III56-66.						
7	Boyle MH, Torrance GW, Sinclair JC. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. <i>N Engl J Med</i> 1983;308(22):1330-7.						
8	Anderson JP, Moser RJ. Parasite screening and treatment among Indochinese refugees: Cost-benefit/utility and the General Health Policy Model. <i>JAMA</i> 1985;253(15):2229-35.						
9	Doubilet P, Weinstein MC, McNeil BJ. The decision concerning coronary angiography in patients with chest pain: A cost-effectiveness analysis. <i>Med Decis Making</i> 1985;5(3):293-309.						
10	Nolan JP, Tarsa NJ, DiBenedetto G. Case-finding for unsuspected thyroid disease: Costs and health benefits. <i>Am J Clin Pathol</i> 1985;83(3):346-55.						
11	van Hout B, Bonsel G, Habbema D. Heart transplantation in the Netherlands: Costs, effects and scenarios. <i>J Health Econ</i> 1993;12:73-93.						
12	Williams A. Economics of coronary artery bypass grafting. <i>BMJ</i> 1985;291(6491):326-9.						
13	Detsky AS, McLaughlin JF, Abrams HB. A cost-utility analysis of the home parenteral nutrition program at the Toronto General Hospital: 1970-1982. <i>JPEN J Parenter Enteral Nutr</i> 1986;10(1):49-57.						
14	Goodwin PJ, Feld, R, Evans, WK. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. <i>J Clin Oncol</i> 1988;6(10):1537-1547.						
15	Hatziaudreu EI, Koplan JP, Weinstein MC. A cost-effective analysis of exercise as a health promotion activity. [erratum: <i>Am J Public Health</i> 1989;March,79(3):273.] <i>Am J Public Health</i> 1988; 78(11):1417-21.						
16	Schneider T, Fagnani F, Lanoe JL. Economic analysis of an immunosuppressive strategy in renal transplantation. <i>Health Policy</i> 1988;9(1):75-89.						
17	Binkin NJ, Koplan JP. The high cost and low efficacy of weekly viral cultures for pregnant women with recurrent genital herpes: A reappraisal. <i>Med Decis Making</i> 1989;9(4):225-30.						
18	Goel V, Deber RB, Detsky AS. Nonionic contrast media: Economic analysis and health policy development. <i>Can Med Assoc J</i> 1989;140(4):389-95.						
19	Tsevat J, Durand-Zaleski I, Pauker SG. Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints. <i>Am J Public Health</i> 1989;79(6):739-43.						
20	Eckman MH, Beshansky JR, Durand-Zaleski I. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves: Does low risk mean high cost? <i>JAMA</i> 1990;263(11):1513-21.						
21	Kievit J, van de Velde CJ. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. <i>Cancer</i> 1990;65:2580-7.						
22	Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. <i>Ann Intern Med</i> 1990;112(3):192-202.						
23	Pickard JD, Bailey S, Sanderson H. Steps towards cost-benefit analysis of regional neurosurgical care. <i>BMJ</i> 1990; 301:629-35.						
24	Russell JG. Is screening for abdominal aortic aneurysm worthwhile? <i>Clin Radiol</i> 1990;41(3):182-4.						
25	Schechter CB, Rose DN, Fahs MC. Tuberculin screening: Cost-effectiveness analysis of various testing schedules. <i>Am J Prev Med</i> 1990;6(3):167-75.						
26	Tosteson AN, Rosenthal DI, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy. <i>Ann Intern Med</i> 1990;113(8):594-603.						
27	Tubman TR, Halliday HL, Normand C. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: A randomised controlled trial. [erratum: <i>BMJ</i> 1991;302(6767):27] <i>BMJ</i> 1990;301(6756):842-5.						
28	Weinstein MC, Tosteson AN. Cost-effectiveness of hormone replacement. <i>Ann N Y Acad Sci</i> 1990;592:162-172.						
29	Weinstein MC, Coley CM, Richter JM. Medical management of gallstones: A cost-effectiveness analysis. <i>J Gen Intern Med</i> 1990;594:277-84						

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i> <i>(listed below)</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
30	Wong JB, Sonnenberg FA, Salem DN. Myocardial revascularization for chronic stable angina. <i>Ann Intern Med</i> 1990;113(11):852-871.						
31	Bass EB, Steinberg EP, Pitt HA. Cost-effectiveness of extracorporeal shock-wave lithotripsy versus cholecystectomy for symptomatic gallstones. <i>Gastroenterology</i> 1991;101(1):189-99.						
32	Beard ME, Inder AB, Allen JR. The costs and benefits of bone marrow transplantation. <i>N Z Med J</i> 1991;104(916):303-5.						
33	Bryan S, Parkin D, Donaldson C. Chiropody and the QALY: A case study in assigning categories of disability and distress to patients. <i>Health Policy</i> 1991;18:169-85.						
34	de Koning HJ, van Ineveld BM, van Oortmarsen GJ. Breast cancer screening and cost-effectiveness: Policy alternatives, quality of life considerations and the possible impact of uncertain factors. <i>Int J Cancer</i> 1991;49(4):531-7.						
35	Drummond MF, Mohide EA, Tew M. Economic evaluation of a support program for caregivers of demented elderly. <i>Int J Technol Assess Health Care</i> 1991;7(2):209-19.						
36	Freedberg KA, Tosteson AN, Cohen CJ. Primary prophylaxis for <i>Pneumocystis carinii</i> pneumonia in HIV-infected people with CD4 counts below 200/mm3: A cost-effectiveness analysis. <i>J Acquir Immune Defic Syndr</i> 1991;4(5):521-31.						
37	Haigh R, Castleen M, Woods K. Management of myocardial infarction in the elderly: Admission and outcome on a coronary care unit. <i>Health Trends</i> 1991;23:154-7.						
38	Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: A decision analysis model. <i>N Engl J Med</i> 1991;324(3):160-8.						
39	Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: A reappraisal. <i>J Hypertens</i> 1991;9(3):199-208.						
40	Lawler FH, Bissonni BS, Holtgrave DR. Circumcision: A decision analysis of its medical value. <i>Fam Med</i> 1991;23(8):587-93.						
41	Stengele U, Baumgartner BR, Chezmar JL. Biliary lithotripsy versus cholecystectomy: A cost-utility analysis. <i>J Lithotripsy Stone Dis</i> 1991;3:133-40.						
42	Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. <i>N Engl J Med</i> 1991;325(2):81-6.						
43	Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. <i>Med J Aust</i> 1992;156(5):312-6.						
44	Freedberg KA, Tosteson AN, Cotton DJ. Optimal management strategies for HIV-infected patients who present with cough or dyspnea: A cost-effective analysis. <i>J Gen Intern Med</i> 1992;7(3):261-72.						
45	Hillner BE, Smith TJ. A model of chemotherapy in node-negative breast cancer. <i>J Natl Cancer Inst</i> 1992;11:143-9.						
46	Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: Estimates using decision analysis while awaiting clinical trial results. <i>JAMA</i> 1992;267(15):2055-61.						
47	Levin LA, Jonsson B. Cost-effectiveness of thrombolysis: A randomized study of intravenous rt-PA in suspected myocardial infarction. <i>Eur Heart J</i> 1992;13(1):2-8.						
48	Bass EB, Pitt HA, Lillemoë KD. Cost-effectiveness of laparoscopic cholecystectomy versus open cholecystectomy. <i>Am J Surg</i> 1993;165(4):466-71.						
49	Birkmeyer JD, Goodnough LT, AuBuchon JP. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. <i>Transfusion</i> 1993;33(7):544-51.						
50	Desch CE, Hillner BE, Smith TJ. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. <i>J Clin Oncol</i> 1993;11(4):777-82.						
51	Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of anticoagulant therapy. <i>N Engl J Med</i> 1993;329:696-702.						
52	Fenton-Lee D, Imrie CW. Pancreatic necrosis: Assessment of outcome related to quality of life and cost of management. <i>Br J Surg</i> 1993;80:1579-82.						
53	Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. <i>Breast Cancer Res Treat</i> 1993;25(2):97-105.						
54	Hogenhuis W, Stevens SK, Wang P. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome. <i>Circulation</i> 1993;88(5 pt 2):11437-46.						
55	Javitt J, Dei Cas R, Chiang YP. Cost-effectiveness of screening and cryotherapy for threshold retinopathy of prematurity. <i>Pediatrics</i> 1993;91(5):859-66.						
56	Eastman RC, Javitt JC, Herman WH. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. <i>Diabetes Care</i> 1997;20(5):735-44.						
57	Kitchen WH, Bowman E, Callanan C. The cost of improving the outcome for infants of birthweight 500-999 g in Victoria: The Victorian Infant Collaborative Study Group. <i>J Paediatr Child Health</i> 1993;29(1):56-62.						
58	Oldridge N, Furlong W, Feeny D. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. <i>Am J Cardiol</i> 1993;72(2):154-61.						
59	Randolph AG, Washington AE, Prober CG. Cesarean delivery for women presenting with genital herpes lesions: Efficacy, risks, and costs. <i>JAMA</i> 1993;270(1):77-82.						
60	Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: A risky business. <i>J Gen Intern Med</i> , 1993;8:476-86.						
61	Smith RD, Hall JA. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chst 1993;158(5):319-22						
62	Kellett J, Clarke J. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected acute myocardial infarction. <i>Med Decis Making</i> 1995;15:297-310.						
63	Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. <i>J Clin Oncol</i> 1993;11(4):771-6.						
64	van der Meulen JH, Steyerberg EW, van der Graaf Y. Age thresholds for prophylactic replacement of Bjork-Shirley convexo-concave heart valves: A clinical and economic evaluation. <i>Circulation</i> 1993;88(1):156-64.						
65	AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma: In search of zero-risk blood supply. <i>JAMA</i> 1994;272(15):1210-4.						
66	Barrett BJ, Parfrey PS, Foley RN. An economic analysis of strategies for the use of contrast media for diagnostic cardiac catheterization. <i>Med Decis Making</i> 1994;14(4):325-35.						
67	Birkmeyer JD, AuBuchon JP, Littenberg B. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. <i>Ann Thorac Surg</i> 1994;57(1):161-8.						
68	Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. <i>J Natl Cancer Inst</i> 1994;86(6):424-30.						
69	Cantor SB, Clover RD, Thompson RF. A decision-analytic approach to postexposure rabies prophylaxis. <i>Am J Public Health</i> 1994;84(7):1144-8.						

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
70	Cohen DJ, Breall JA, Ho KK. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: Use of a decision-analytic model. <i>Circulation</i> 1994;89(4):1859-74.						
71	Gabriel SE, Campion ME, O'Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. <i>Arthritis Rheum</i> 1994;37(3):333-41.						
72	Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. <i>Aust J Public Health</i> 1994;18(2):153-160.						
73	Goodnough LM, Grishaber JE, Birkmeyer JD. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. <i>Urology</i> 1994;44(2):226-31.						
74	Harris A, Hendrie D, Bower C. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. <i>Med J Aust</i> 1994;160(8):483-8.						
75	Hatziandreu EJ, Brown RE, Revicki DA. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. <i>Pharmacoeconomics</i> 1994;5:249-68.						
76	Katz DA, Cronenwett JL. The cost-effectiveness of early surgery versus watchful waiting in the management of small abdominal aortic aneurysms. <i>J Vasc Surg</i> 1994;19(6):980-990.						
77	Kiberd BA. Should hepatitis C-infected kidneys be transplanted in the United States? <i>Transplantation</i> 1994;57(7):1068-72.						
78	Krahn MD, Mahoney JE, Eckman MH. Screening for prostate cancer: A decision analytic view. <i>JAMA</i> 1994;272:773-80.						
79	Launois R, Henry B, Marty JR. Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation. <i>Pharmacoeconomics</i> 1994;6:453-63.						
80	Laupacis A, Bourne R, Rorabeck C. Cost of elective total hip arthroplasty during the first year: Cemented versus noncemented. <i>J Arthroplasty</i> 1994;9(5):481-7.						
81	Le Floch JP, Charles MA, Phillipon C. Cost effectiveness of screening for microalbuminuria using immunochemical dipstick tests or laboratory assays in diabetic patients. <i>Diabet Med</i> 1994;11:349-56.						
82	McIntyre P, Hall J, Leeder S. An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease. <i>Aust J Public Health</i> 1994;18(4):394-400.						
83	Nease RF Jr., Owens DK. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. <i>Med Decis Making</i> 1994;14(4):382-92.						
84	Oster G, Huse DM, Lacey MJ. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. <i>Stroke</i> 1994;25(6):1149-56.						
85	Provenzale D, Kemp JA, Arora S. A guide for surveillance of patients with Barrett's esophagus. <i>Am J Gastroenterol</i> 1994;89(5):670-80.						
86	Smith KJ, Pesce RR. Pulmonary artery catheterization in exacerbations of COPD requiring mechanical ventilation: A cost-effectiveness analysis. <i>Respir Care</i> 1994;39:961-7.						
87	Tousignant P, Cosio MG, Levy RD. Quality adjusted life years added by treatment of obstructive sleep apnea. <i>Sleep</i> 1994;17(1):52-60.						
88	Zbrozek AS, Cantor SB, Cardenas MP. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. <i>Am J Hospital Pharm</i> 1994;51(12):1555-63.						
89	Adams PC, Gregor JC, Kertesz AE. Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database. <i>Gastroenterology</i> 1995;109:177-88.						
90	Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: Prevalence and cost-effectiveness. <i>Hepatology</i> 1995;22:1720-7.						
91	Boer R, de Koning HJ, van Oortmarssen GJ. In search of the best upper age limit for breast cancer screening. <i>Eur J Cancer</i> 1995;31A:2040-3.						
92	Busch MP, Korelitz JJ, Kleinman SH. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. <i>Transfusion</i> 1995;35:903-10.						
93	Colice GL, Birkmeyer JD, Black WC. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. <i>Chest</i> 1995;108:1264-71.						
94	Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alpha: An economic appraisal. <i>Hepatology</i> 1995;22:1863-73.						
95	Eckman MH, Greenfield S, Mackey WC. Decision and cost-effectiveness analyses. <i>JAMA</i> 1995;273:712-20.						
96	Lee KH, Angus DC, Abramson NS. Cardiopulmonary resuscitation: What cost to cheat death? <i>Crit Care Med</i> 1996;24:2046-52.						
97	Etchason J, Petz L, Keeler E. The cost effectiveness of preoperative autologous blood donations. <i>N Engl J Med</i> 1995;332(11):719-24.						
98	Gage BF, Cardinalli AB, Albers GW. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with non-valvular atrial fibrillation. <i>JAMA</i> 1995;274:1839-45.						
99	Glimelius B, Hoffman K, Graf W. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. <i>Ann Oncol</i> 1995;6:267-74.						
100	Glutzer DE, Freedberg KA, Bauchner H. Management of childhood lead poisoning: clinical impact and cost-effectiveness. <i>Med Decis Making</i> 1995;15(1):13-24.						
101	Gournay K, Brooking J. The community psychiatric nurse in primary care: An economic analysis. <i>J Adv Nurs</i> 1995;22:769-78.						
102	Harris JP, Anderson JP, Novak R. An outcomes study of cochlear implants in deaf patients: Audiologic, economic, and quality-of-life changes. <i>Arch Otolaryngol Head Neck Surg</i> 1995;121(4):398-404.						
103	Hunink MG, Wong JB, Donaldson MC. Revascularization for femoropopliteal disease: A decision and cost-effectiveness analysis. <i>JAMA</i> 1995;274(2):165-71.						
104	Jonsson B, Christiansen C, Johnell O. Cost-effectiveness of fracture prevention in established osteoporosis. <i>Osteoporosis Int</i> 1995;5(2):136-42.						
105	Kalish SC, Gurwitz JH, Krumholz HM. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. <i>J Gen Intern Med</i> 1995;10:321-30.						
106	Kamlet MS, Paul N, Greenhouse J. Cost utility analysis of maintenance treatment for recurrent depression. <i>Control Clin Trials</i> 1995;16(1):17-40.						
107	Kent KC, Kuntz KM, Patel MR. Perioperative imaging strategies for carotid endarterectomy: An analysis of morbidity and cost-effectiveness in symptomatic patients. <i>JAMA</i> 1995;274:888-93.						
108	Kerridge RK, Glasziou PP, Hillman KM. The use of "quality-adjusted life years" (QALYs) to evaluate treatment in intensive care. <i>Anaesth Intensive Care</i> 1995;23:322-31.						
109	Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation. <i>BMJ</i> 1995;311:1595-9.						

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
110	Kievit J, Bruinvels DJ. Detection of recurrence after surgery for colorectal cancer. Eur J Cancer 1995;31A:1222-5.						
111	King JT, Glick HA, Mason TJ. Elective surgery for asymptomatic, unruptured, intracranial aneurysms: A cost-effectiveness analysis. J Neurosurg 1995;83:403-12.						
112	Lawrence WF, Grist TM, Brazy PC. Magnetic resonance angiography in progressive renal failure: A technology assessment. Am J Kidney Dis 1995;25(5):701-9.						
113	Edelson JT, Weinstein MC, Tosteson ANA. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263(3):408-13.						
114	Lea AR, Hailey DM. The cochlear implant: A technology for the profoundly deaf. Med Prog Technol 1995;21:47-52.						
115	Mangtani P, Hall AJ, Normand CE.alternative strategies in England and Wales. J Epidemiol Community Health 1995;49:238-44.						
116	Patterson RE, Eisner RL, Horowitz SF. Comparison of C-E & utility of exercise ECG, single photon emission computed tomography, PET, & coronary angiography for diagnosis of coronary artery disease. Circulation 1995;91(1):54-65.						
117	Paul JE, Mauskopf JA, Bell L. Cost-consequence models for varicella-zoster virus infections. Pharmacotherapy 1995;15:49S-58S.						
118	Ramsey SD, Patrick DL, Albert RK. The cost-effectiveness of lung transplantation: A pilot study. Chest 1995;108:1594-1601.						
119	Revicki DA, Brown RE, Palmer W. Modeling the cost effectiveness of antidepressant treatment in primary care. PharmacoEconomics 1995;8:524-40.						
120	Ross-Degnan D, Soumerai SB, Avorn J. Hemophilia home treatment: Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995;11(2):327-44.						
121	Shepard DS, Walsh JA, Kleinau E. Setting priorities for the Children's Vaccine Initiative: A cost-effectiveness approach. Vaccine 1995;13:707-14.						
122	Tsevat J, Duke D, Goldman L. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:914-9.						
123	Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in the Netherlands. Bone Marrow Transplant 1995;16:463-70.						
124	Velanovich V. Immediate biopsy versus observation for abnormal findings on mammograms: An analysis of potential outcomes and costs. Am J Surg 1995;170:327-32.						
125	Wimo A, Mattson B, Krakau I. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995;11(1):49-65.						
126	Wong JB, Koff BS, Tine F. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122(9), 664-75.						
127	Yin D, Baum RA, Carpenter JP. Cost-effectiveness of MR angiography in cases of limb-threatening peripheral vascular disease. Radiology 1995;194:757-64.						
128	Diabetes Control & Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409-15.						
129	Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. PharmacoEconomics 1996;9:443-54.						
130	Bennett CL, Matchar D, McCrory D. Cost-effective models for flutamide for prostate carcinoma patients: Are they helpful for policy makers? Cancer 1996; 77:1854-61						
131	Brasel KJ, Weigelt JA. Blunt thoracic aortic trauma: A cost-utility approach for injury detection. Arch Surg 1996;131:619-25.						
132	Chang RW, Pellissier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996;275:858-65.						
133	Danese MD, Powe NR, Sawin CT. Screening for mild thyroid failure at the periodic health examination. JAMA 1996;276:285-92.						
134	Derdeyn CP, Powers WJ. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. Stroke 1996;27:1944-50.						
135	Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996;275:1247-51.						
136	Goossens ME, Rutten-van Molken M, Leidl RM. A randomized clinical trial. II. Economic evaluations. J Rheumatol 1996;23:1246-54.						
137	Gottlieb RH, Mooney C, Mushlin AI. The prostate: Decreasing cost-effectiveness of biopsy with advancing age. Invest Radiol 1996;31:84-90.						
138	Gregor JC, Ponich TP, Detsky AS. Should ERCP be routine after an episode of "idiopathic" pancreatitis? A cost-utility analysis. Gastrointest Endosc 1996;44:118-23.						
139	Holohan TV. Cost-effectiveness modeling of simultaneous pancreas-kidney transplantation. Int J Technol Assess Health Care 1996;12:416-24.						
140	Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: The cost-effectiveness of a behavioral group intervention. Am J Public Health 1996;86(10):1442-5.						
141	Hutton J, Brown R, Borowitz M. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics 1996;9S2:8-22.						
142	James M, St Leger S, Rowsell KV. Prioritizing elective care: A cost utility analysis of orthopaedics in the northwest of England. J Epidemiol Community Health 1996;50:182-9.						
143	Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164-9.						
144	Jonsson B, Christiansen C, Johnell O. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 1996;103:30-8						
145	Jordan JE, Marks MP, Lane B. Cost-effectiveness of endovascular therapy in the surgical management of cerebral arteriovenous malformations. AJNR Am J Neuroradiol 1996;17:247-54.						
146	Kattan MW, Inoue Y, Giles FJ. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996;125:541-8.						
147	Kuntz KM, Tsevat J, Goldman L. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94:957-65.						
148	Kunz K, Kuppermann M, Bowe T. Protein A immunoadsorption column versus splenectomy in the treatment of steroid-resistant immune thrombocytopenic purpura. Int J Technol Assess Health Care 1996;12:436-49.						
149	Langlotz CP, Schnall MD, Malkowicz SB. Cost-effectiveness of endorectal magnetic resonance imaging for the staging of prostate cancer. Acad Radiol 1996;3S1:S24-7.						

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
150	Launois R, Reboul-Marty J, Henry B. A cost-utility analysis of second line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine. <i>PharmacoEconomics</i> 1996;10:504-21.						
151	Livartowski A, Boucher J, Detournay B. Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. <i>Vaccine</i> 1996;14:495-500.						
152	Malter AD, Larson EB, Urban N. Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. <i>Spine</i> 1996;21:1048-54.						
153	Nichol G, Laupacis A, Stiell IG. Cost-effectiveness analysis of potential improvements to emergency medical services for victims of out-of hospital cardiac arrest. <i>Ann Emerg Med</i> 1996;27:711-20.						
154	Norum J, Angelsen V, Wist E. Treatment costs in Hodgkin's disease: A cost-utility analysis. <i>Eur J Cancer</i> 1996;32A:1510-7.						
155	Nussbaum ES, Heros RC, Erickson DL. Cost-effectiveness of carotid endarterectomy. <i>Neurosurgery</i> 1996;38:237-44.						
156	Oh PI, Maerov P, Pritchard D. A cost-utility analysis of second line antibiotics in the treatment of acute otitis media in children. <i>Clin Ther</i> 1996;18:160-82.						
157	Richards DM, Irving MH. Cost-utility analysis of home parenteral nutrition. <i>Br J Surg</i> 1996;83:1226-9.						
158	Schulman KA, Linas BP. Pharmacoeconomics: State of the art in 1997. <i>Int J Technol Assess Health Care</i> 1996;12:698-713.						
159	Sculpher M, Michaels J, McKenna MA. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. <i>Int J Technol Assess Health Care</i> 1996;12:104-25.						
160	St Leger AS, Spencely M, McColloum CN. Screening for abdominal aortic aneurysm: A computer assisted cost-utility analysis. <i>Eur J Vasc Endov Surg</i> 1996;11:183-90.						
161	Tolias CM, Choksey MS. Will increased awareness among physicians of the significance of sudden agonizing headache affect the outcome of subarachnoid hemorrhage? <i>Stroke</i> 1996;27:807-12.						
162	Wyatt JR, Niparko JK, Rothman M. Cost utility of the multichannel cochlear implant in 58 profoundly deaf individuals. <i>Laryngoscope</i> 1996;106:816-21.						
163	Zhang M, Owen RR, Pope SK. Cost-effectiveness of clozapine monitoring after the first 6 months. <i>Arch Gen Psychiatry</i> 1996;53:954-8.						
164	AuBuchon JP, Birkmeyer JD, Busch MP. Cost effectiveness of expanded human immunodeficiency virus testing protocols for donated blood. <i>Transfusion</i> 1997;37:45-51.						
165	Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: A cost-utility analysis of office-based strategies. <i>J Fam Pract</i> 1997;44:49-60.						
166	Brasel KJ, Borgstrom DC, Weigelt JA. Cost-utility analysis of contaminated appendectomy wounds. <i>J Am Coll Surgeons</i> 1997;184:23-30.						
167	Brothers TE, Frank CE, Frank B. Is duplex venous surveillance worthwhile after arthroplasty? <i>J Surg Res</i> 1997;67:72-8.						
168	Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. <i>J Clin Psychopharmacol</i> 1997;17:298-307.						
169	Cronenwett JL, Birkmeyer JD, Nackman GB. Cost-effectiveness of carotid endarterectomy in asymptomatic patients. <i>J Vasc Surg</i> 1997;25:298-309.						
170	Victorian Infant Collaborative Study Group. Economic outcome for intensive care of infants of birthweight 500-999g born in Victoria in the post surfactant era. <i>J Paediatr Child Health</i> 1997;33:202-8.						
171	Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: A cost-utility study. <i>J Fam Pract</i> 1997;44:545-55.						
172	Eckman MH, Steere AC, Kalish RA. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. <i>N Engl J Med</i> 1997;337:357-63.						
173	Graham JD, Thompson KM, Goldie SJ. The cost-effectiveness of air bags by seating position. <i>JAMA</i> 1997;278:1418-25.						
174	Hamel MB, Phillips RS, Davis RB. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. <i>Ann Intern Med</i> 1997;127:195-202.						
175	Heudebert GR, Marks R, Wilcox CM. Choice of long term strategy for the management of patients with severe esophagitis: A cost-utility analysis. <i>Gastroenterology</i> 1997;112:1078-86.						
176	Hillner BE, Kirkwood JM, Atkins MB. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from eastern cooperative oncology group 1684. <i>J Clin Oncol</i> 1997;15:2351-8.						
177	Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. <i>Acta Oncol</i> 1997;36S9:1-60.						
178	Huber TS, McGorray SP, Carlton LC. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: A decision analysis model. <i>J Vasc Surg</i> 1997;25:984-94.						
179	Hummel S, Piercy J, Wright R. An economic analysis of the survival and ventricular enlargement (SAVE) study: Application to the United Kingdom. <i>PharmacoEconomics</i> 1997;12:182-92.						
180	King JT, Sperling MR, Justice AC. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. <i>J Neurosurg</i> 1997;87:20-8.						
181	Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. <i>Epilepsia</i> 1997;38:154-63.						
182	Lee TT, Solomon NA, Heidenreich PA. Cost-effectiveness of screening for carotid stenosis in asymptomatic patients. <i>Ann Intern Med</i> 1997;126:337-46.						
183	Liberato NL, Quaglino S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. <i>J Clin Oncol</i> 1997;15:2673-82.						
184	Mushlin AI, Mooney C, Holloway RG. The cost effectiveness of magnetic resonance imaging for patients with equivocal neurological symptoms. <i>Int J Technol Assess Health Care</i> 1997;13:21-34.						
185	Nord E, Wisloff F, Hjorth M. Cost-utility analysis of melphalan plus prednisone with or without interferon-a2b in newly diagnosed multiple myeloma. <i>PharmacoEconomics</i> 1997;12:89-103.						
186	Norum J, Vonen B, Olsen JA. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: A cost-effectiveness analysis. <i>Ann Oncol</i> 1997;8:65-70.						
187	Obuchowski NA, Modic MT, Magdinec M. Assessment of the efficacy of noninvasive screening for patients with asymptomatic neck bruits. <i>Stroke</i> 1997;28:1330-9.						
188	Owens DK, Sanders GD, Harris RA. Cost-effectiveness of implantable cardioverter defibrillator relative to amiodarone for prevention of sudden cardiac death. <i>Ann Intern Med</i> 1997;126:1-12.						
189	Pinkerton SD, Holtgrave DR, Valdisseri RO. Cost-effectiveness of HIV-prevention skills training for men who have sex with men. <i>AIDS</i> 1997;11(3):347-57.						

Catalog of Preference Scores

<i>ICD-9 Category</i>	<i>Reference #</i>	<i>Health State</i>	<i>Preference Score</i>	<i>Range</i>	<i>Preferences Determined by</i>	<i>Measurement Technique</i>	<i>Generic Scale</i>
	<i>(listed below)</i>						
190	Raab SS, Hornberger J. The effect of a patient's risk-taking attitude on the cost-effectiveness of testing strategies in the evaluation of pulmonary lesions. <i>Chest</i> 1997;111:1583-90.						
191	Revicki DA, Brown RE, Keller MB. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. <i>J Clin Psychiatry</i> 1997;58:47-58.						
192	Salkeld G, Phongsavan P, Oldenburg B. The cost-effectiveness of a cardiovascular risk reduction program in general practice. <i>Health Policy</i> 1997;41:105-19.						
193	Seto TB, Taira DA, Tsevat J. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: A decision analytic model for patients admitted to hospital with atrial fibrillation. <i>J Am Coll Cardiol</i> 1997;29:122-30.						
194	Teran JC, Imperiale TF, Mullen KD. Primary prophylaxis of variceal bleeding in cirrhosis: A cost effectiveness analysis. <i>Gastroenterology</i> 1997;112:473-82.						
195	Townsend J, Buxton M. Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy. <i>Health Policy</i> 1997;39:181-94.						
196	Trallori G, Messori A. Drug treatments for maintaining remission in Crohn's disease: A lifetime cost-utility analysis. <i>Pharmacoeconomics</i> 1997;11:444-53.						
197	Fahs MC, Mandelblatt JS. Cost effectiveness of cervical cancer screening among elderly low-income women. In book: <i>Preventing Disease: Beyond the Rhetoric</i> , 1990:441-46.						
198	Rose DN, Schechter CB, Silver A. Cost effectiveness of isoniazid chemoprophylaxis. In book: <i>Preventing Disease: Beyond the Rhetoric</i> , 1990:446-54.						
199	Nissinen A, Tuomilehto J, Kottke TE. Cost-effectiveness of the North Karelia Hypertension Program: 1972-1977. <i>Med Care</i> 1986;24:767-80.						
200	Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. <i>Eur Heart J</i> 1991;12:694-9.						
201	Jacobson JJ, Schweitzer SO, Kowalski CJ. Chemoprophylaxis of prosthetic joint patients during dental treatment: A decision-utility analysis. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i> 1991;72:167-77.						
202	Kelly AE, Haddix AC, Scanlon KS. Cost-effectiveness of strategies to prevent neural tube defects. In: Gold MR et al. <i>Cost-Effectiveness in Health and Medicine</i> , pp. 314-48. Oxford University Press; 1996.						
203	Stinnett AA, Mittleman, MA, Weinstein MC. C-E of dietary & pharmacologic therapy for cholesterol reduction in adults. In: Gold MR et al. <i>Cost-Effectiveness in Health and Medicine</i> , pp. 349-91. Oxford University Press; 1996.						
204	Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. <i>Arch Intern Med</i> 1997;177(17):1972-80.						
205	Mooney MM, Mettlin C, Michalek AM. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: A cost-effectiveness analysis. <i>Cancer</i> 1997;80(6):1052-64.						
206	Johannesson M, Meltzer D, O'Connor RM. Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of hypertension. <i>Med Decis Making</i> 1997;17(4):382-9.						
207	Hornberger JC, Best JH, Garrison LP, Jr. Cost-effectiveness or repeat medical procedures: Kidney transplantation for an example. <i>Med Decis Making</i> 1997;17(4):363-72.						
208	Sisk JE, Moskowitz AJ, Whang W. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. <i>JAMA</i> 1997;278(16):1333-9.						
209	Kim WR, Poterucha JJ, Hermans JE. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. <i>Ann Intern Med</i> 1997;127(10):866-74.						
210	McNamara RL, Lima JA, Whelton PK. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: A cost-effectiveness analysis. <i>Ann Intern Med</i> 1997;127(9):775-87.						
211	Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. <i>Ann Oncol</i> 1997;8(11):1081-7.						
212	Lavernia CJ, Guzman JF, Gachupin-Garcia A. Cost effectiveness and quality of life in knee arthroplasty. <i>Clin Orthop</i> 1997;Dec(345):134-9.						
213	Norum J, Olsen JA, Wist EA. Lumpectomy or mastectomy? Is breast conserving surgery too expensive? <i>Breast Cancer Res Treat</i> 1997;45(1):7-14.						
214	Messori A, Becagli P, Berto V. Advanced HIV infection treated with zidovudine monotherapy. <i>Ann Pharmacother</i> 1997;31(2):1447-54.						
215	Smith S, Weber S, Wibilin T. Cost-effectiveness of hepatitis A vaccination in health care workers. <i>Infect Control Hosp Epidemiol</i> 1997;18(10):688-91.						
216	Bennett WG, Yuji I, Beck R. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. <i>Ann Intern Med</i> 1997;127:855-66.						
217	Moore RD, Chiasson RE. Cost-utility analysis of prophylactic treatment with ganciclovir for cytomegalovirus retinitis. <i>J Acquir Immune Defic Syndr Hum Retroviro</i> 1997;16:15-21.						
218	Ortega A, Dranitsaris G, Sturgeon J, et al. A cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. <i>Gynecol Oncol</i> 1997;66:454-463						
219	Hall J. A cost-utility analysis of mammography screening in Australia. <i>Soc Sci Med</i> 1992;34:993-1004						
220	Laupacis A, Keown P, Pus N. A study of the quality of life and cost-utility of renal transplantation. <i>Kidney Int</i> 1996;50:235-242.						
221	Brodin H, Persson J. Cost-utility analysis of assistive technologies in the European Commission's TIDE program. <i>Int J Technol Assess Health Care</i> 1995;11:276-283						
222	Bisonni RS, Lawler FH, Pierce L. Recurrent otitis media: A cost-utility analysis of simulated treatment using tympanostomy tubes vs antibiotic prophylaxis. <i>Fam Pract Res J</i> 1991;11:371-378.						
223	Bisonni RS, Lawler FH, Holtgrave DR. Transurethral prostatectomy versus transurethral dilatation of the prostatic urethra for benign prostatic hyperplasia: A cost-utility analysis. <i>Fam Pract Res J</i> 1993;12:25-36.						
224	Evans AR, Seeger T, Leinhardt M. Cost-utility analysis of cochlear implants. <i>Ann Otol Rhinol Laryngol</i> 1995;166:239-40.						
225	Shiell A, Smith RD. A tentative cost-utility analysis of road safety education. <i>Aust. J Public Health</i> 1993;17:128-30.						
226	Wimo A, Wallin J-O, Lundgren K. Impact of day care on dementia patients: Costs, well-being and relatives' views. <i>Fam Pract</i> 1990;7(4):279-87.						
227	Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: Methodological issues and results. <i>Health Econ</i> 1994;3:157-68.						
228	Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. <i>AJNR Am J Neuroradiol</i> 1997;18:1453-62.						